For O
dispelling O
wind-dampness B-NEG
and O
dispersing O
coldness B-NEG

-DOCSTART- O

Strengthen O
the O
heart B-DNP
and O
replenish O
qi O
, O
activating O
yang O
and O
blood B-DNP
circulation I-DNP
, O
promoting O
the O
restoration B-POS
of I-POS
consciousness I-POS
with O
drugs O
of O
fragnant O
flavour O
, O
relieving O
pain B-NEG
. O

-DOCSTART- O

break O
blood B-DNP

-DOCSTART- O

HER2-overexpressing O
breast B-NEG
cancer I-NEG

-DOCSTART- O

Type O
2 O
Diabetes B-NEG
Mellitus I-NEG
. O

-DOCSTART- O

tinea B-NEG
favosa I-NEG
; O
mouth-corner B-NEG
ulcer I-NEG

-DOCSTART- O

To O
arrest O
seminal B-NEU
emission I-NEU
, O
to O
restrain O
urination B-NEU
, O
and O
to O
check O
diarrhea B-NEG
. O
cturnal B-NEU
emission I-NEU
, O
spermatorrhea B-NEG
, O
enuresis B-NEG
, O
frequent B-NEG
urination I-NEG
, O
abnormal B-NEG
uterine I-NEG
bleeding I-NEG
, O
excessive O
leukorrhea B-NEG
, O
protracted O
diarrhea B-NEG
, O
chronic B-NEG
dysentery I-NEG
. O

-DOCSTART- O

For O
nutritional O
supplementation O
, O
also O
for O
treating O
dietary B-NEG
shortage I-NEG
or O
imbalance B-NEG
. O

-DOCSTART- O

Treatment O
of O
headache B-NEG
and O
dizziness B-NEG
, O
costal O
and O
abdomina O
pain B-NEG
, O
spasmodic O
pain B-NEG
of O
the O
limbs O
, O
anemia B-NEG
, O
menstrual B-NEG
disorders I-NEG
, O
spontaneous O
sweating B-NEU
and O
night B-NEU
sweating I-NEU
. O

-DOCSTART- O

Chronic B-NEG
Hepatitis I-NEG
B I-NEG

-DOCSTART- O

To O
invigorate O
the O
function O
of O
the O
kidney B-DNP
, O
to O
alleviate O
asthma B-NEG
, O
and O
to O
relieve O
diarrhea B-NEG
. O

-DOCSTART- O

Angina B-NEG
pectoris I-NEG
, O
cerebral B-NEG
atherosclerosis I-NEG
, O
diffusive O
intravascular B-NEG
clotting I-NEG
, O
thrombophlebitis B-NEG
, O
hepatitis B-NEG
, O
acute B-NEG
surgical I-NEG
infection I-NEG
, O
mastitis B-NEG
, O
erysipelas B-NEG
, O
otitis B-NEG
media I-NEG
, O
tonsillitis B-NEG
, O
bone B-NEG
marrow I-NEG
infection I-NEG
, O
menstrual B-NEG
disorder I-NEG
, O
dysmenorrhea O
, O
amenorrhea B-NEG
, O
postpartum B-NEG
stasis I-NEG
stagnation I-NEG
abdominal I-NEG
pain I-NEG
, O
pain B-NEG
in O
heart O
and O
abdomen O
, O
concretion B-NEG
conglomeration I-NEG
accumulation I-NEG
and O
gathering O
, O
heat B-NEU
impediment O
swelling B-NEG
and O
pain B-NEG
, O
knocks B-NEG
and O
falls B-NEG
, O
heat B-NEU
entering O
construction-blood B-NEG
, O
vexation B-NEG
and O
agitation B-NEG
, O
insomnia B-NEG
and O
vexation B-NEG
, O
swelling B-NEG
toxin O
of O
welling O
abscess B-NEG
and O
sore B-NEG
, O
zoster B-NEG
, O
neurodermatitis B-NEG
, O
psoriasis B-NEG
. O

-DOCSTART- O

Tiotropium O
is O
a O
muscarinic O
receptor O
antagonist O
, O
often O
referred O
to O
as O
an O
antimuscarinic O
or O
anticholinergic O
agent O
. O
Although O
it O
does O
not O
display O
selectivity O
for O
specific O
muscarinic O
receptors O
, O
on O
topical O
application O
it O
acts O
mainly O
on O
M3 O
muscarinic O
receptors O
located O
in O
the O
airways B-DNP
to O
produce O
smooth B-POS
muscle I-POS
relaxation I-POS
, O
thus O
producing O
a O
bronchodilatory B-POS
effect I-POS
. O

-DOCSTART- O

Intravenous O
Anesthetic O
Interaction O
Unrecognized B-NEG
Condition I-NEG

-DOCSTART- O

Dimethindene O
can O
also O
be O
used O
as O
an O
adjuvant O
in O
eczema B-NEG
and O
other O
pruriginous B-NEG
dermatoses I-NEG
of O
allergic O
origin O
. O

-DOCSTART- O

Investigated O
for O
use/treatment O
in O
adverse O
effects O
( O
chemotherapy O
) O
and O
bone B-DNP
marrow I-DNP
transplant O
. O

-DOCSTART- O

For O
ascariasis B-NEG
and O
taeniasis B-NEG
. O
For O
constipation B-NEG
due O
to O
dryness O
of O
intestine O
. O

-DOCSTART- O

soothe O
diaphragm B-DNP

-DOCSTART- O

To O
nourish O
blood B-DNP
, O
stanch B-NEG
bleeding I-NEG
, O
calm O
liver B-DNP
, O
moisten O
dryness O
. O

-DOCSTART- O

Heart B-NEG
Failure I-NEG
. O

-DOCSTART- O

Neurological B-DNP
systems I-DNP
, O
Neurological B-DNP
systems I-DNP
health I-DNP

-DOCSTART- O

relieve O
cough B-NEG

-DOCSTART- O

affection O
by O
cold B-NEG
1 O
common O
cold B-NEG
2 O
influenza B-NEG

-DOCSTART- O

dyspnea B-NEG
due O
to O
lung-heat B-NEU

-DOCSTART- O

fever B-NEG
with O
overstrain B-NEG

-DOCSTART- O

Its O
aqueous O
infusion O
inhibits O
the O
growth O
of O
skin O
fungi O
such O
as O
Trichophyton O
violaceum O
. O

-DOCSTART- O

Acute B-NEG
Mania I-NEG

-DOCSTART- O

abdominal B-NEG
distension I-NEG
; O
abdominal B-NEG
fullness I-NEG

-DOCSTART- O

insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk O
, O
Body O
weight O
regulation O
, O
Woman O
, O
Reproductive B-DNP
systems I-DNP
, O
Diet O
related O
cardiovascular B-NEG
disease I-NEG
, O
Endocrine O
& O
reproductive B-DNP
systems I-DNP
, O
Intelligence O
, O
Dermatological B-DNP
systems I-DNP
health O
, O
Eldery O
, O
Overall O
CVD O
, O
Mimmuietabolic O
rate/energy O
expenditure O
, O
General O
woman O
, O
General O
skin B-DNP
health I-DNP
, O
menopausal B-DNP
woman I-DNP
, O
Others O
, O
Hemostatic B-DNP
function I-DNP
, O
Mental B-DNP
state I-DNP
and O
performance O
, O
Man O

-DOCSTART- O

abdominal O
pain B-NEG

-DOCSTART- O

Treatment O
of O
mass B-NEG
in O
the O
abdomen O
, O
goitre B-NEG
with O
pain B-NEG
, O
epigastric B-NEG
pain I-NEG
and O
distension B-NEG
due O
to O
indigestion B-NEG
. O

-DOCSTART- O

Decanoyl O
acetaldehyde O
is O
bacteriostatic O
and O
fungistatic O
. O

Its O
decoction O
retards O
the O
progress O
of O
tuberculosis B-NEG
experimentally O
. O

Synthetic O
product O
( O
compound O
of O
decanoyl O
acetaldehyde O
and O
NaHSO3 O
) O
promotes O
white B-NEU
cell I-NEU
phagocytosis I-NEU
. O

Anti-inflammation B-POS
. O

Quercitrin O
, O
an O
active O
component O
, O
is O
a O
strong O
diuretic O
, O
and O
exerts O
such O
effect O
in O
a O
1 O
: O
10 O
, O
0 O
solution O
. O

-DOCSTART- O

Urinary B-DNP
system I-DNP
health I-DNP
, O
Endocrine O
& O
reproductive B-DNP
systems I-DNP
, O
Reproductive B-DNP
systems I-DNP
, O
Urinary B-DNP
systems I-DNP
, O
Others O
, O
Man O

-DOCSTART- O

Intravenous O
injection O
or O
oral O
administration O
of O
berberine O
exerts O
a O
hypotensive B-NEU
effect I-NEU
on O
experimental O
animals O
. O

-DOCSTART- O

To O
warm O
the O
spleen B-DNP
, O
stop O
vomiting B-NEG
, O
clear O
away O
summer-heat B-NEG
and O
eliminate O
dampness B-NEG
. O

-DOCSTART- O

destroy O
intestinal B-NEG
parasites I-NEG

-DOCSTART- O

blood B-NEG
stagnation I-NEG
caused O
by O
falling O
or O
strike O

-DOCSTART- O

Used O
in O
the O
treatment O
of O
relapsing O
forms O
of O
multiple B-NEG
sclerosis I-NEG
( O
MS B-NEG
) O
. O

-DOCSTART- O

Unresectable O
Metastasis O
Originating O
in O
Colonic B-NEG
Cancer I-NEG
. O

-DOCSTART- O

soothe O
the O
sinews B-DNP
and O
invigorate O
the O
network B-NEU
vessels O

-DOCSTART- O

constipation B-DNP
and O
dry B-NEG
stool I-NEG

-DOCSTART- O

For O
tonifying O
weakness B-NEG

-DOCSTART- O

distribution O
) O
, O
energy O
supply O
and O
recovery O
, O
Mental B-DNP
state I-DNP
and I-DNP
performance I-DNP
, O
Man O

-DOCSTART- O

Clarithromycin O
also O
inhibits O
the O
hepatic O
microsomal O
CYP3A4 O
isoenzyme O
and O
P-glycoprotein O
, O
an O
energy-dependent O
drug O
efflux O
pump O
. O

-DOCSTART- O

constrain O
the O
lung B-DNP

-DOCSTART- O

warm O
the O
menses B-NEU
and O
stop O
bleeding B-NEG

-DOCSTART- O

clear O
heat B-NEU
and O
cool O
blood B-NEU

-DOCSTART- O

wind-heat B-NEG
; O

wind B-NEG
and O
heat B-NEG
; O

wind-heat B-NEG
pathogene I-NEG
wind B-NEG
and O
heat B-NEG
blended O
as O
a O
pathogenic B-NEG
factor I-NEG
. O

-DOCSTART- O

Rosuvastatin O
is O
a O
competitive O
inhibitor O
of O
HMG-CoA O
reductase O
, O
which O
reductase O
catalyzes O
the O
conversion O
of O
HMG-CoA O
to O
mevalonate O
, O
an O
early O
rate-limiting O
step O
in O
cholesterol O
biosynthesis O
. O

Lapaquistat O
acetate O
is O
a O
squalene O
synthase O
inhibitor O
investigated O
for O
the O
treatment O
of O
hypercholesterolemia B-NEG
. O

-DOCSTART- O

Treatment O
of O
bdominal O
pain B-NEG
and O
constipation B-NEG
due O
to O
cold B-NEG
or O
retention O
of O
food O
in O
the O
intestines O
. O

-DOCSTART- O

Treatment O
of O
stagnation O
of O
undigested O
meat O
with O
epigastric B-NEG
distension I-NEG
, O
diarrhea B-NEG
and O
abdominal B-NEG
pain I-NEG
, O
amenorrhea B-NEG
due O
to O
blood B-NEG
stasis I-NEG
, O
epigastric B-NEG
pain I-NEG
or O
abdominal B-NEG
colic I-NEG
, O
after O
childbirth O
, O
heraial O
pain B-NEG
, O
hyperlipemia B-NEG
. O

-DOCSTART- O

Lysophospholipids O
have O
been O
found O
to O
mediate O
the O
activity O
of O
this O
drug O
. O

-DOCSTART- O

Damp-heat B-NEG
diarrhea I-NEG
, O
vaginal B-NEG
discharge I-NEG
, O
hemorrhoids B-NEG
, O
pain B-NEG
from O
swollen O
welling O
abscess B-NEG
, O
scrofula B-NEG
. O

-DOCSTART- O

impetigo B-NEG
; O
pyoderma B-NEG

-DOCSTART- O

Breast B-NEG
Pain I-NEG

-DOCSTART- O

Palonosetron O
is O
a O
selective O
serotonin O
5-HT O
3 O
receptor O
antagonist O
. O

The O
antiemetic O
activity O
of O
the O
drug O
is O
brought O
about O
through O
the O
inhibition O
of O
5-HT B-DNP
3 I-DNP
receptors I-DNP
present O
both O
centrally O
( O
medullary O
chemoreceptor O
zone O
) O
and O
peripherally O
( O
GI O
tract O
) O
. O

This O
inhibition O
of O
5-HT B-DNP
3 I-DNP
receptors I-DNP
in O
turn O
inhibits O
the O
visceral B-NEG
afferent I-NEG
stimulation I-NEG
of I-NEG
the I-NEG
vomiting I-NEG
center I-NEG
, O
likely O
indirectly O
at O
the O
level O
of O
the O
area O
postrema O
, O
as O
well O
as O
through O
direct O
inhibition O
of O
serotonin B-DNP
activity I-DNP
within O
the O
area O
postrema O
and O
the O
chemoreceptor O
trigger O
zone O
. O

Alternative O
mechanisms O
appear O
to O
be O
primarily O
responsible O
for O
delayed O
nausea B-NEG
and O
vomiting B-NEG
induced O
by O
emetogenic O
chemotherapy O
, O
since O
similar O
temporal O
relationships O
between O
between O
serotonin O
and O
emesis O
beyond O
the O
first O
day O
after O
a O
dose O
have O
not O
been O
established O
, O
and O
5-HT O
3 O
receptor O
antagonists O
generally O
have O
not O
appeared O
to O
be O
effective O
alone O
in O
preventing O
or O
ameliorating O
delayed O
effects O
. O

It O
has O
been O
hypothesized O
that O
palonosetron's O
potency O
and O
long O
plasma O
half-life O
may O
contribute O
to O
its O
observed O
efficacy O
in O
preventing O
delayed O
nausea B-NEG
and O
vomiting B-NEG
caused O
by O
moderately O
emetogenic O
cancer O
chemotherapy O
. O

-DOCSTART- O

Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Mood O
, O
Quality O
of O
life O
, O
Inflammation O
, O
Other B-DNP
system I-DNP
health I-DNP
, O
Others O
, O
Mental B-DNP
state I-DNP
and I-DNP
performance I-DNP

-DOCSTART- O

tidal O
fever B-NEG
in O
the O
afternoon O

-DOCSTART- O

For O
cases O
of O
collapse O
due O
to O
massive O
hemorrhage B-NEG
manifested O
as O
cold B-NEG
limbs I-NEG
, O
oily B-NEG
sweat I-NEG
, O
pale B-NEG
complexion I-NEG
, O
spiritlessness B-NEG
, O
small B-NEG
and I-NEG
indistinct I-NEG
pulse I-NEG
, O
use O
high O
grade O
of O
Radix O
Ginseng O
( O
such O
as O
Ginseng O
Korea O
or O
Ginseng O
Jilin O
) O
instead O
of O
Codonopsis O
Pilosulae O
. O

-DOCSTART- O

release O
the O
exterior O
and O
dispel O
wind B-NEG

-DOCSTART- O

Used O
in O
the O
treatment O
of O
Kaposi's B-NEG
sarcoma I-NEG
and O
cancer B-NEG
of O
the O
lung O
, O
ovarian O
, O
and O
breast O
. O

AbraxaneÂ® O
is O
specfically O
indicated O
for O
the O
treatment O
of O
metastatic B-NEG
breast I-NEG
cancer I-NEG
and O
locally O
advanced B-NEG
or I-NEG
metastatic I-NEG
non-small I-NEG
cell I-NEG
lung I-NEG
cancer I-NEG
. O

-DOCSTART- O

This O
is O
a O
symptom O
with O
fullness B-NEG
and O
pain B-NEG
in I-NEG
the I-NEG
chest I-NEG
and I-NEG
abdomen I-NEG
. O

-DOCSTART- O

To O
remove O
heat B-NEG
from O
the O
lung O
and O
relieve O
sore B-NEG
throat I-NEG
, O
and O
to O
regulate O
the O
flow O
of O
qi O
of O
the O
liver O
and O
the O
stomach O
. O

-DOCSTART- O

cough B-NEG
due O
to O
phlegm B-NEG

-DOCSTART- O

Macular B-NEG
Edema I-NEG

-DOCSTART- O

Investigated O
for O
use/treatment O
in O
hepatitis B-NEG
( O
viral O
, O
B O
) O
. O

-DOCSTART- O

anal B-NEG
fistula I-NEG
hemorrhoids B-NEG
complicated O
by O
anal B-NEG
fistula I-NEG
. O

-DOCSTART- O

For O
acute O
and O
long-term O
management O
of O
signs O
and O
symptoms O
of O
osteoarthritis B-NEG
and O
rheumatoid B-NEG
arthritis I-NEG
, O
as O
well O
as O
for O
the O
management O
of O
pain B-NEG
. O

-DOCSTART- O

The O
large O
hydrophilic O
molecule O
is O
able O
to O
form O
hydrogen O
bond O
interactions O
with O
the O
terminal O
D-alanyl-D-alanine O
moieties O
of O
the O
NAM/NAG-peptides O
, O
which O
is O
normally O
a O
five-point O
interaction O
. O

-DOCSTART- O

1 O
An O
active O
component O
arcitiin O
is O
a O
vasodilator O
and O
hypotensive O
. O
2 O
. O
Over O
dosage O
of O
arctiin O
may O
lead O
to O
convulsion B-NEG
and O
respiratory B-NEG
failure I-NEG
. O

-DOCSTART- O

Endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
Reproductive B-DNP
systems I-DNP

-DOCSTART- O

swelling B-NEG
of O
carbuncle B-NEG
is O
lumped O
at O
the O
neck O

-DOCSTART- O

flatulence B-NEG
in O
the O
abdomen O
and O
below O
the O
xyphoid O
process O

-DOCSTART- O

suffering B-NEG
from O
diarrhea B-NEG
and O
having O
a O
stomachache B-NEG

-DOCSTART- O

Chronic B-NEG
Hepatitis I-NEG
B I-NEG
Virus I-NEG
, O
Pediatric O

-DOCSTART- O

Liver B-DNP
health I-DNP
, O
Liver B-DNP
, O
Others O

-DOCSTART- O

blood B-NEG
vacuity I-NEG
, O
septicemia B-NEG
, O
menstrual B-NEG
disorder I-NEG
, O
numbness B-NEG
and O
paralysis B-NEG
, O
aching B-NEG
in O
lumbus O
and O
legs O
. O

-DOCSTART- O

Treatment O
of O
deficient O
yin O
of O
the O
liver O
and O
kidneys O
and O
hyperactivity O
of O
liver O
yang O
manifested O
as O
distension O
and O
pain B-NEG
in O
the O
head O
and O
eyes O
, O
dizziness B-NEG
and O
vertigo B-NEG
. O

Red O
ochre O
( O
Daizheshi O
) O
is O
used O
with O
Dragon's O
bone O
( O
Longgu O
) O
, O
Oyster O
shell O
( O
Muli O
) O
, O
White O
peony O
root O
( O
Bais O

-DOCSTART- O

Blood B-NEG
stasis I-NEG
in O
the O
hypochondriac O
region O
due O
to O
traumatic B-NEG
injury I-NEG
characterised O
by O
hypochondriac B-NEG
pain I-NEG
. O

Traumatic B-NEG
swelling I-NEG
pain I-NEG
, O
intercostal B-NEG
neuralgia I-NEG
, O
costal B-NEG
chrondritis I-NEG
marked O
by O
accumulation O
of O
blood B-NEG
stasis I-NEG
can O
be O
treated O
by O
the O
modified O
recipe O
. O

-DOCSTART- O

To O
tonify O
Qi O
and O
strengthen O
the O
spleen B-DNP
. O

To O
consolidate O
the O
Chong B-DNP
channel I-DNP
and O
control O
the O
blood B-DNP
. O

-DOCSTART- O

amenorrhea B-NEG
; O
menstrual B-NEG
block I-NEG
absence I-NEG
or O
suppression B-NEG
of I-NEG
menstruation I-NEG
. O

-DOCSTART- O

To O
promote O
contraction B-NEU
and O
stem B-NEU
desertion I-NEU
, O
disperse O
swelling B-NEG
and O
relieve O
pain B-NEG
. O

-DOCSTART- O

cough B-NEG
due O
to O
dryness B-NEG
of I-NEG
the I-NEG
lung I-NEG

-DOCSTART- O

Thioridazine O
blocks O
postsynaptic O
mesolimbic O
dopaminergic O
D1 O
and O
D2 O
receptors O
in O
the O
brain B-DNP
; O
blocks O
alpha-adrenergic O
effect O
, O
depresses O
the O
release O
of O
hypothalamic B-DNP
and I-DNP
hypophyseal I-DNP
hormones I-DNP
and O
is O
believed O
to O
depress O
the O
reticular B-DNP
activating I-DNP
system I-DNP
thus O
affecting O
basal B-DNP
metabolism I-DNP
, O
body B-NEU
temperature I-NEU
, O
wakefulness B-NEG
, O
vasomotor B-NEU
tone I-NEU
, O
and O
emesis B-NEG
. O

-DOCSTART- O

reinforce O
blood B-DNP

-DOCSTART- O

distribution O
) O
, O
insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk I-NEG
, O
Body B-NEU
weight I-NEU
regulation I-NEU

-DOCSTART- O

To O
warm O
and O
replenish O
qi O
and O
blood B-NEU
. O

-DOCSTART- O

repel O
all O
malign O
sore B-NEG

-DOCSTART- O

Kidney B-NEG
Failure I-NEG
, I-NEG
Chronic I-NEG

-DOCSTART- O

Treatment O
of O
deficiency B-NEG
of I-NEG
spleen I-NEG
and I-NEG
stomach I-NEG
, O
lassitude B-NEG
, O
palpitation B-NEG
, O
arrhythmia B-NEG
. O

-DOCSTART- O

Fructus O
Crataegi O
( O
charred O
) O
: O
Has O
more O
digestant O
action O
and O
is O
particularly O
useful O
for O
stagnation O
of O
undigested O
meat O
and O
diarrhea B-NEG
with O
inadequate O
discharge O
from O
the O
bowels B-DNP
. O

-DOCSTART- O

cough B-NEG
due O
to O
phlegm-damp B-NEG
due O
to O
lung-heat B-NEU

-DOCSTART- O

To O
boost O
essence O
, O
brighten O
eyes B-DNP
, O
cool O
blood B-DNP
and O
resolve O
toxin B-NEG
. O

-DOCSTART- O

cough B-NEG
due O
to O
lung B-DNP
subcutaneous I-DNP
nodes I-DNP

-DOCSTART- O

1 O
Its O
decoction O
enhances O
th O
intestinal B-NEG
contraction I-NEG
and O
tensity B-NEG
of O
rabbits O
in O
vitro O
, O
which O
can O
be O
counteracted O
by O
atropine O
. O
2 O
. O
Inhibiting O
the O
growth O
of O
sarcoma B-NEG
180 I-NEG
in O
mice O
. O

-DOCSTART- O

An O
inhibition O
of O
DNA B-DNP
polymerase I-DNP
. O

-DOCSTART- O

tinea B-NEG

-DOCSTART- O

Dexamethasone O
is O
a O
glucocorticoid O
agonist O
. O

-DOCSTART- O

For O
the O
treatment O
of O
EGFR-expressing O
, O
metastatic B-NEG
colorectal I-NEG
carcinoma I-NEG
that O
is O
refractory O
to O
fluoropyrimidine- O
, O
oxaliplatin- O
, O
and O
irinotecan- O
containing O
chemotherapy O
regimens O
. O

-DOCSTART- O

The O
powder O
of O
Croton O
seed O
( O
Badou O
) O
is O
blown O
into O
the O
throat B-DNP
to O
cause O
vomiting B-NEG
. O

-DOCSTART- O

stop O
thirst B-NEG

-DOCSTART- O

Hemophilia B-NEG
A I-NEG

-DOCSTART- O

To O
eliminate O
mass O
, O
reduce O
fullness B-NEG
, O
strengthen O
spleen B-DNP
and O
regulate O
stomach B-DNP
. O

-DOCSTART- O

insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk I-NEG
, O
Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Digestion B-NEU
, O
absorption B-NEU
, O
Lipid O
profile O
, O
Improvement O
of O
blood B-NEU
glucose I-NEU
levels I-NEU
, O
Body B-NEU
weight I-NEU
regulation I-NEU
, O
Diet B-NEG
related I-NEG
cardiovascular I-NEG
disease I-NEG
, O
motility B-NEU
, O
Evacuation B-NEU

-DOCSTART- O

nfantile B-NEG
convulsive I-NEG
seizure I-NEG
due O
to O
fright O

-DOCSTART- O

Indicated O
as O
symptomatic O
treatment O
of O
allergic B-NEG
reactions I-NEG
: O
urticaria B-NEG
, O
allergies B-NEG
of O
the O
upper O
respiratory O
tract O
such O
as O
hey B-NEG
fever I-NEG
and O
perennial B-NEG
rhinitis I-NEG
, O
food O
and O
drug O
allergies B-NEG
; O
pruritus B-NEG
of O
various O
origins O
, O
except O
pruritus B-NEG
due O
to O
cholestasis B-NEG
; O
insect B-NEG
bites I-NEG
. O

-DOCSTART- O

Rikkunshito O
improves O
globus B-NEG
sensation I-NEG
in O
patients O
with O
proton-pump O
inhibitor-refractory O
laryngopharyngeal O
reflux O
. O

-DOCSTART- O

Fever B-NEG
, O
Sweats B-NEU
, O
and O
Hot B-NEG
Flashes I-NEG

-DOCSTART- O

To O
clear O
heat B-NEG
and O
cool O
blood B-DNP
; O

To O
benefit O
qi O
and O
contain O
blood B-DNP
; O

To O
revitalize O
blood B-DNP
and O
desolve O
stagnation B-NEG

-DOCSTART- O

restlessness B-NEG
and O
thirst B-NEU
; O
polydipsia B-NEG

-DOCSTART- O

Myelodysplastic B-NEG
Syndromes I-NEG

-DOCSTART- O

This O
is O
a O
syndrome O
with O
palpitation B-NEG
and O
severe O
palpitation B-NEG
. O

-DOCSTART- O

Hyperactivity B-NEG
of O
the O
liver-yang O
, O
hypertension B-NEG
, O
dizziness B-NEG
, O
vertigo B-NEG
, O
insomnia B-NEG
, O
amnesia B-NEG
. O

-DOCSTART- O

Diet O
related O
cardiovascular B-NEG
disease I-NEG
, O
Hemostatic B-NEU
function I-NEU

-DOCSTART- O

Knocks B-NEG
and O
falls B-NEG
, O
stasis B-NEG
swelling I-NEG
pain I-NEG
, O
wind-damp B-NEG
impediment I-NEG
pain I-NEG
. O

-DOCSTART- O

dissipate O
stasis B-NEG

-DOCSTART- O

Vaginal B-NEG
Diseases I-NEG

-DOCSTART- O

Endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
Reproductive B-DNP
systems I-DNP
, O
Strength B-POS
and O
power B-POS
, O
Physical B-DNP
performance I-DNP
and O
fitness B-POS

-DOCSTART- O

a O
disease O
that O
menstruation B-NEU
is O
not O
even O
due O
to O
coldness B-NEG

-DOCSTART- O

To O
warm O
the O
kidney B-DNP
, O
invigorate O
yang O
, O
replenish O
the O
vital B-POS
essence I-POS
and O
reinforce O
the O
marrow B-DNP

-DOCSTART- O

To O
transform O
dampness O
and O
promote O
water B-NEU
metabolism I-NEU
. O

-DOCSTART- O

Hepatocellular B-NEG
Carcinoma I-NEG

-DOCSTART- O

Anemia B-NEG
in I-NEG
Chronic I-NEG
Renal I-NEG
Disease I-NEG

-DOCSTART- O

fever B-NEG

-DOCSTART- O

old O
ulceration B-NEG

-DOCSTART- O

Breast B-NEG
Cancer I-NEG

-DOCSTART- O

Diabetic B-NEG
Neuropathy I-NEG
, O
Painful O

-DOCSTART- O

To O
replenish O
the O
liver B-DNP
and O
the O
kidney B-DNP
, O
and O
to O
arrest O
bleeding B-NEG
by O
removing O
heat B-NEU
from I-NEU
blood I-NEU
. O

-DOCSTART- O

Hydrochlorothiazide O
allows O
the O
blood B-DNP
vessels I-DNP
to O
relax O
and O
causes O
kidneys B-DNP
to O
remove O
more O
salt B-DNP
and I-DNP
water I-DNP
from I-DNP
the I-DNP
blood I-DNP
in O
order O
to O
reduce O
blood B-DNP
volume I-DNP
. O

Valsartan O
is O
in O
a O
group O
of O
drugs O
called O
angiotensin O
II O
receptor O
antagonists O
. O

Valsartan O
keeps O
blood B-DNP
vessels I-DNP
from O
narrowing O
, O
which O
lowers O
blood B-NEU
pressure I-NEU
and O
improves O
blood B-NEU
flow I-NEU
. O

-DOCSTART- O

eliminate O
vexation B-NEG
and O
thirst B-NEU

-DOCSTART- O

muscular B-NEG
twitching I-NEG
and O
cramp B-NEG
; O

twitching B-NEG
of I-NEG
muscles I-NEG

-DOCSTART- O

invigorate O
the O
network O
vessels O

-DOCSTART- O

dizziness B-NEG
; O
vertigo B-NEG

-DOCSTART- O

IMC-A12 O
is O
a O
fully O
human O
monoclonal O
antibody O
that O
specifically O
targets O
the O
type O
1 O
human O
insulin-like O
growth O
factor O
receptor O
( O
IGF-IR O
) O
. O

Tumors B-NEG
have O
receptors O
for O
the O
insulin-like O
growth O
factor-1 O
( O
IGF-I O
) O
, O
and O
it O
is O
thought O
that O
the O
presence O
of O
these O
receptors O
cause O
tumors B-NEG
to O
grow O
. O

IMC-A12 O
attaches O
to O
the O
receptors O
and O
may O
inhibit O
the O
growth B-NEG
of I-NEG
cancer I-NEG
cells I-NEG
. O

-DOCSTART- O

Emergence B-NEG
Agitation I-NEG

-DOCSTART- O

pain B-NEG
in O
the O
supraorbital O
bone O

-DOCSTART- O

To O
remove O
blood B-NEG
stasis I-NEG
, O
promote O
the O
subsidence O
of O
swelling B-NEG
, O
relieve O
pain B-NEG
and O
arrest O
bleeding B-NEG
. O

-DOCSTART- O

Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Protective B-NEU
immunity I-NEU

-DOCSTART- O

moisten B-NEU
face I-NEU

-DOCSTART- O

deafness B-NEG

-DOCSTART- O

Specifically O
, O
dalbavancin O
prevents O
incorporation O
of O
N-acetylmuramic B-DNP
acid I-DNP
( O
NAM)- O
and O
N-acetylglucosamine B-DNP
( I-DNP
NAG)-peptide I-DNP
subunits O
from O
being O
incorporated O
into O
the O
peptidoglycan O
matrix O
; O
which O
forms O
the O
major O
structural O
component O
of O
Gram-positive O
cell O
walls O
. O

-DOCSTART- O

Major B-NEG
Depressive I-NEG
Disorder I-NEG

-DOCSTART- O

Purging B-NEG
by O
moisterizing O

-DOCSTART- O

cool O
blood B-DNP
and O
stop O
bleeding B-NEG

-DOCSTART- O

diarrhea B-NEG

dysentery B-NEG

-DOCSTART- O

To O
supplement O
qi O
and O
nourish O
yin O
, O
clear O
fire O
and O
engender O
liquid O
. O

-DOCSTART- O

Imipenem O
acts O
as O
an O
antimicrobial O
through O
the O
inhibition O
of O
cell B-DNP
wall I-DNP
synthesis I-DNP
which O
leads O
to O
rapid O
cell B-DNP
lysis I-DNP
and O
death O
without O
filament B-DNP
formation I-DNP
. O
Cilastatin O
helps O
imipenem O
work O
more O
effectively O
by O
preventing O
the O
breakdown O
of O
the O
antibiotic O
in O
the O
kidneys B-DNP
. O

-DOCSTART- O

Food B-NEG
accumulation I-NEG
, O
stomachache B-NEG
, O
abdomin B-NEG
al I-NEG
pain I-NEG
. O

-DOCSTART- O

ischuria B-NEG
; O
dysuria B-NEG
; O
retention B-NEG
of I-NEG
urine I-NEG

-DOCSTART- O

bloody B-NEG
dysentery I-NEG

-DOCSTART- O

wind B-NEG
stroke I-NEG
1 O
apoplexy B-NEG
2 O
invasion O
of O
wind B-NEG
pathogen I-NEG
3 O
wind-stroke B-NEG
syndrome I-NEG
syndrome O
due O
to O
external O
affection O
by O
the O
pathogenic B-NEG
wind I-NEG
, O
manifested O
by O
fever B-NEG
, O
headache B-NEG
, O
perspiration B-NEG
, O
slow B-NEG
and I-NEG
floating I-NEG
pulse I-NEG
. O

-DOCSTART- O

Cisplatin O
binds O
to O
nucleophilic O
groups O
such O
as O
GC-rich O
sites O
in O
DNA O
, O
inducing O
intrastrand O
and O
interstrand O
DNA O
cross-links O
, O
as O
well O
as O
DNA-protein O
cross-links O
. O

-DOCSTART- O

Treatment O
of O
: O
1 O
Hemorrhages B-NEG
due O
to O
external B-NEG
injuries I-NEG
. O
Dragon's O
blood B-DNP
( O
Xuejie O
) O
can O
be O
taken O
alone O
for O
external O
use O
, O
or O
it O
can O
be O
combined O
with O
Cattail O
pollen O
( O
Puhuang O
) O
. O

-DOCSTART- O

cosolidate O
the O
kidney B-DNP

-DOCSTART- O

dyspnea B-NEG
with O
coughing B-NEG

-DOCSTART- O

Corylifolinin O
( O
isobavachalcone O
) O
dilates O
coronary B-DNP
artery I-DNP
significantly O
. O

-DOCSTART- O

Treatment O
of O
arthralgia B-NEG
with O
weakness B-NEG
of O
the O
loins O
and O
knees O
, O
excessive B-NEG
menstrual I-NEG
flow I-NEG
, O
chronic B-NEG
phthisical I-NEG
cough I-NEG
. O

-DOCSTART- O

black B-POS
hair I-POS

-DOCSTART- O

Cyclophosphamide's O
active O
metabolites O
aldophosphamide O
and O
phosphoramide O
mustard O
bind O
to O
DNA O
, O
thereby O
inhibiting O
DNA B-NEU
replication I-NEU
and O
initiating O
cell B-NEU
death I-NEU
. O

-DOCSTART- O

ThioTEPA O
is O
used O
a O
as O
conditioning O
treatment O
prior O
to O
allogeneic O
or O
autologous O
haematopoietic O
progenitor O
cell O
transplantation O
( O
HPCT O
) O
in O
haematological B-NEG
diseases I-NEG
in O
adult O
and O
paediatric O
patients O
. O

Also O
, O
when O
high O
dose O
chemotherapy O
with O
HPCT O
support O
it O
is O
appropriate O
for O
the O
treatment O
of O
solid B-NEG
tumours I-NEG
in O
adult O
and O
paediatric O
patients O
. O

-DOCSTART- O

Glucagon O
binds O
the O
glucagon O
receptor O
, O
a O
G O
protein-coupled O
receptor O
located O
in O
the O
plasma B-DNP
membrane I-DNP
, O
which O
then O
initiates O
a O
dual O
signaling O
pathway O
using O
both O
adenylate O
cyclase O
activation O
and O
increased O
intracellular B-DNP
calcium I-DNP
. O

Adenylate O
cyclase O
manufactures O
cAMP O
( O
cyclic O
AMP O
) O
, O
which O
activates O
protein B-DNP
kinase I-DNP
A I-DNP
( O
cAMP-dependent B-DNP
protein I-DNP
kinase I-DNP
) O
. O

This O
enzyme O
, O
in O
turn O
, O
activates O
phosphorylase B-DNP
kinase I-DNP
, O
which O
, O
in O
turn O
, O
phosphorylates O
glycogen O
phosphorylase O
, O
converting O
into O
the O
active O
form O
called O
phosphorylase O
A O

Phosphorylase O
A O
is O
the O
enzyme O
responsible O
for O
the O
release O
of O
glucose-1-phosphate O
from O
glycogen O
polymers O
. O

This O
yields O
glucose O
molecules O
to O
be O
released O
into O
the O
blood B-DNP
. O

Glucagon O
receptors O
are O
found O
in O
the O
liver B-DNP
, O
kidney B-DNP
, O
brain B-DNP
and O
pancreatic B-DNP
islet I-DNP
cells I-DNP
. O

The O
glucagon O
mediated O
signals O
lead O
to O
an O
increase O
in O
insulin B-NEU
excretion I-NEU

-DOCSTART- O

Linezolid O
selectively O
inhibits O
bacterial B-NEU
protein I-NEU
synthesis I-NEU
through O
binding O
to O
sites O
on O
the O
bacterial O
ribosome O
and O
prevents O
the O
formation B-NEU
of I-NEU
a I-NEU
functional I-NEU
70B-initiation I-NEU
complex I-NEU
. O

Isoniazid O
appears O
to O
block O
the O
synthesis B-NEU
of I-NEU
mycolic I-NEU
acids I-NEU
, O
major O
components O
of O
the O
mycobacterial O
cell O
wall O
. O

This O
agent O
is O
only O
active O
against O
actively O
growing O
mycobacteria O
because O
, O
as O
a O
pro-drug O
, O
it O
requires O
activation O
in O
susceptible O
mycobacterial O
species O
. O

Rifampin O
acts O
via O
the O
inhibition O
of O
DNA-dependent B-DNP
RNA I-DNP
polymerase I-DNP
, O
leading O
to O
a O
suppression B-DNP
of I-DNP
RNA I-DNP
synthesis I-DNP
and O
cell B-NEU
death I-NEU
. O

-DOCSTART- O

To O
remove O
heat O
from O
the O
lung B-DNP
, O
and O
to O
relieve O
cough B-NEG
and O
dyspnea B-NEG
. O

-DOCSTART- O

Treatment O
of O
thrist B-NEG
in O
febrile O
disease O
, O
dry B-NEG
cough I-NEG
due O
to O
heat B-NEG
in O
the O
lung O
, O
diabetes B-NEG
caused O
by O
internal O
heat O
, O
sores B-NEG
and O
abscess B-NEG
. O

-DOCSTART- O

Ocular B-NEG
Hypertension I-NEG

-DOCSTART- O

Liver B-NEG
Disease I-NEG

-DOCSTART- O

flaccidity B-NEG
and O
limping B-NEG

-DOCSTART- O

To O
remove O
blood B-NEG
stasis I-NEG
and O
promote O
the O
blood B-NEU
flow I-NEU
, O
to O
stimulate O
menstrual B-NEG
discharge I-NEG
, O
and O
to O
induce O
labour O
. O

-DOCSTART- O

insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk I-NEG
, O
Body B-NEU
weight I-NEU
regulation I-NEU
, O
Improvement O
of O
blood B-NEU
glucose I-NEU
levels I-NEU
, O
Body B-NEU
weight I-NEU

-DOCSTART- O

Valproic O
Acid O
acts O
by O
increasing O
gamma-aminobutyric O
acid O
levels O
in O
the O
brain O
or O
by O
altering O
the O
properties O
of O
voltage O
dependent O
sodium O
channels O
. O

Lamotrigine O
inhibits O
voltage-sensitive O
sodium O
channels O
and/or O
calcium O
channels O
, O
thereby O
stabilizing O
neuronal B-DNP
membranes I-DNP
and O
consequently O
modulating O
presynaptic O
transmitter O
release O
of O
excitatory O
amino O
acids O
. O

-DOCSTART- O

cough B-NEG

-DOCSTART- O

relaxing O
apoplexy B-NEG

-DOCSTART- O

To O
pacify O
the O
liver B-DNP
and O
subdue O
the O
yang O
; O

To O
conduct O
rebellious O
qi O
downward O
and O
stop O
vomiting B-NEG
; O

To O
stop O
bleeding B-NEG

-DOCSTART- O

Imatinib O
binds O
to O
an O
intracellular O
pocket O
located O
within O
tyrosine O
kinases O
( O
TK O
) O
, O
thereby O
inhibiting O
ATP B-NEU
binding I-NEU
and O
preventing O
phosphorylation B-NEU
and O
the O
subsequent O
activation B-NEU
of I-NEU
growth I-NEU
receptors I-NEU
and O
their O
downstream O
signal B-DNP
transduction I-DNP
pathways I-DNP
. O

Temozolomide O
is O
converted O
at O
physiologic O
pH O
to O
the O
short-lived O
active O
compound O
, O
monomethyl O
triazeno O
imidazole O
carboxamide O
( O
MTIC O
) O
. O

The O
cytotoxicity B-NEG
of O
MTIC O
is O
due O
primarily O
to O
methylation B-NEU
of I-NEU
DNA I-NEU
at O
the O
O6 O
and O
N7 O
positions O
of O
guanine O
, O
resulting O
in O
inhibition O
of O
DNA B-NEU
replication I-NEU
. O

-DOCSTART- O

Obesity B-NEG

-DOCSTART- O

diarrhea B-NEG
due O
to O
damp-heat B-NEG

-DOCSTART- O

Pulmonary B-NEG
Arterial I-NEG
Hypertension I-NEG

-DOCSTART- O

Doxapram O
produces O
respiratory O
stimulation O
mediated O
through O
the O
peripheral O
carotid O
chemoreceptors O
. O

It O
is O
thought O
to O
stimulate O
the O
carotid B-DNP
body I-DNP
by O
inhibiting O
certain B-DNP
potassium I-DNP
channels I-DNP
. O

-DOCSTART- O

Wind-cold-damp B-NEG
impediment I-NEG
, O
paralysis B-NEG
, O
painful O
wound B-NEG
from O
knocks B-NEG
and O
falls B-NEG
, O
tetanus B-NEG
. O

-DOCSTART- O

Kidney B-DNP
Transplant O

-DOCSTART- O

have O
no O
menstruation B-DNP
due O
to O
static O
blood B-NEU
. O

-DOCSTART- O

Endometriosis B-NEG

-DOCSTART- O

1 O
To O
clear O
heat B-NEU
and O
toxic B-NEG
material I-NEG
, O
deprive O
dampness B-NEU
and O
kill O
parasites B-NEG
. O

For O
sorethroat B-NEG
, O
dysentery B-NEG
, O
trichomonas B-NEG
enteritis I-NEG
, O
toothache B-NEG
, O
stomachache B-NEG
and O
leucorrhagia B-NEU
, O
external O
use O
for O
tinea B-NEG
and O
eczema B-NEG
. O

2 O
To O
relieve O
dyspnea B-NEG
and O
cough B-NEG
. O

3 O
Anticarcinogenic B-POS
. O
For O
malignant B-NEG
hydatidiform I-NEG
mole I-NEG
, O
chorionic B-NEG
epithelioma I-NEG
and O
leukemia B-NEG
. O

-DOCSTART- O

fracture B-NEG

-DOCSTART- O

stop O
tearing B-NEG

-DOCSTART- O

clear O
heat B-NEU
and O
moisten O
the O
lung B-DNP

-DOCSTART- O

nine O
kinds O
of O
illness B-NEG
due O
to O
disturbance O
of O
Gi O

-DOCSTART- O

Enduring O
cough B-NEG
and O
asthma B-NEG
, O
bronchitis B-NEG
, O
lumbago B-NEG
and O
limp O
leg B-DNP
, O
frequent O
urination B-NEU
, O
enuresis B-NEG
, O
impotence B-NEG
, O
emission B-NEU
, O
intestinal B-NEG
dry I-NEG
and O
constipation B-NEG
, O
stone B-NEG
strangury I-NEG
, O
sores B-NEG
and O
scrofula B-NEG
. O

-DOCSTART- O

Atrophy B-NEG

-DOCSTART- O

Intelligence B-POS
, O
Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Others O
, O
Protective O
immunity B-NEU
, O
Mental B-DNP
state I-DNP
and I-DNP
performance I-DNP

-DOCSTART- O

the O
body O
is O
fatigued O
and O
cannot O
walk O
because O
of O
a O
flaccidity B-NEG
of I-NEG
lower I-NEG
limbs I-NEG

-DOCSTART- O

skin B-NEG
disease I-NEG
on O
palms O
. O

-DOCSTART- O

abdominal B-NEG
pain I-NEG
and O
tenesmus B-NEG

-DOCSTART- O

Traumatic B-NEG
brain I-NEG
injury I-NEG

-DOCSTART- O

stop O
sweating B-NEU

-DOCSTART- O

For O
the O
treatment O
of O
chronic B-NEG
hepatitis I-NEG
B O
in O
adult O
and O
adolescent O
patients O
6 O
years O
of O
age O
with O
evidence O
of O
viral O
replication O
and O
either O
evidence O
of O
persistent O
elevations O
in O
serum O
aminotransferases O
( O
ALT O
or O
AST O
) O
or O
histologically B-NEG
active I-NEG
disease I-NEG
. O

-DOCSTART- O

Ipilimumab O
is O
a O
fully O
human O
IgG1 O
antibody O
that O
binds O
to O
CTLA-4 O
( O
cytotoxic O
T O
lymphocyte-associated O
antigen O
4 O
) O
, O
a O
molecule O
on O
T-cells O
that O
is O
indicated O
for O
unresectable B-NEG
or I-NEG
metastatic I-NEG
melanoma I-NEG
. O

The O
absence O
or O
presence O
of O
CTLA-4 O
can O
augment O
or O
suppress O
the O
immune B-DNP
system's I-DNP
T-cell O
response O
in O
fighting O
disease B-NEG
. O

Ipilimumab O
is O
designed O
to O
block O
the O
activity O
of O
CTLA-4 O
, O
thereby O
sustaining O
an O
active B-DNP
immune I-DNP
response I-DNP
in O
its O
attack O
on O
cancer B-NEG
cells I-NEG
. O

The O
proposed O
mechanism O
of O
action O
is O
indirect O
, O
and O
may O
be O
through O
T-cell O
- O
mediated O
anti-tumor B-DNP
immune I-DNP
responses I-DNP
. O

-DOCSTART- O

Doxorubicin O
forms O
complexes O
with O
DNA O
by O
intercalation O
between O
base O
pairs O
, O
and O
it O
inhibits O
topoisomerase O
II O
activity O
by O
stabilizing O
the O
DNA-topoisomerase O
II O
complex O
, O
preventing O
the O
religation O
portion O
of O
the O
ligation-religation O
reaction O
that O
topoisomerase O
II O
catalyzes O
. O

-DOCSTART- O

Croton O
seed O
( O
Badou O
) O
is O
used O
with O
Rhubarb O
( O
Dahuang O
) O
and O
Dried O
ginger O
( O
Ganjiang O
) O
in O
the O
formula O
Sanwu O
Beiji O
Wan O
. O

-DOCSTART- O

To O
supplement O
blood B-DNP
, O
quicken B-NEU
blood I-NEU
, O
strengthen O
lumbus B-DNP
and O
knees B-DNP
. O

-DOCSTART- O

invigorate O
blood B-DNP

-DOCSTART- O

Binds O
to O
the O
nicotinic O
acetycholine O
receptors O
( O
by O
virtue O
of O
its O
similarity O
to O
acetylcholine O
) O
in O
the O
motor O
endplate O
and O
blocks O
access O
to O
the O
receptors O
. O

-DOCSTART- O

unconsciousness B-NEG

-DOCSTART- O

Encainide O
is O
a O
sodium O
channel O
blocker O
, O
binding O
to O
voltage B-DNP
gated I-DNP
sodium I-DNP
channels I-DNP
. O

It O
stabilizes O
the O
neuronal B-DNP
membrane I-DNP
by O
inhibiting O
the O
ionic B-NEU
fluxes I-NEU
required O
for O
the O
initiation O
and O
conduction O
of O
impulses O
. O

Ventricular O
excitability O
is O
depressed O
and O
the O
stimulation O
threshold O
of O
the O
ventricle O
is O
increased O
during O
diastole O
. O

-DOCSTART- O

Edema B-NEG
due O
to O
deficiency B-NEG
in I-NEG
the I-NEG
kidney I-NEG
, O
accompanied O
with O
heaviness O
sensation O
in O
the O
loins O
and O
knees O
and O
oliguria O
; O

retention O
of O
body O
fluid O
with O
dyspnea B-NEG
and O
cough B-NEG
. O

-DOCSTART- O

To O
benefit O
vital B-POS
energy I-POS
to O
control O
blood B-DNP
. O

-DOCSTART- O

Cold B-NEG
pain I-NEG
in O
stomach O
duct O
and O
abdomen O
, O
indigestion B-NEG
, O
cold B-NEG
mounting O
with O
abdominal O
pain B-NEG
, O
menstrual B-NEG
disorder I-NEG
. O

-DOCSTART- O

Endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Reproductive B-DNP
systems I-DNP
, O
Urinary B-DNP
system I-DNP
health I-DNP
, O
Urinary B-DNP
systems I-DNP
, O
Inflammation B-NEG
, O
Others O

-DOCSTART- O

illness B-NEG

-DOCSTART- O

moisten O
the O
lung B-DNP

-DOCSTART- O

promote O
the O
large O
intestine B-DNP

-DOCSTART- O

Treament O
of O
vertigo B-NEG
, O
tinnitus B-NEG
, O
weakness B-NEG
in I-NEG
the I-NEG
loins I-NEG
and I-NEG
knees I-NEG
, O
premature B-NEG
whitening I-NEG
of I-NEG
hair I-NEG
and O
impaired B-NEG
eyesight I-NEG
due O
to O
deficiency O
of O
yin O
of O
the O
liver O
and O
kidney O
. O

-DOCSTART- O

Liver B-NEG
cancer I-NEG

-DOCSTART- O

Fluoxetine O
is O
an O
antidepressant O
belonging O
to O
the O
selective O
serotonin O
reuptake O
inhibitor O
( O
SSRI O
) O
class O
, O
and O
blocks O
the O
reuptake B-NEU
of I-NEU
serotonin I-NEU
at O
the O
serotonin O
reuptake O
pump O
of O
the O
neuronal O
membrane O
, O
enhancing O
the O
actions B-NEU
of I-NEU
serotonin I-NEU
on O
5HT<sub>1A</sub> O
autoreceptors O
. O

Quetiapine's O
antipsychotic O
activity O
is O
likely O
due O
to O
a O
combination O
of O
antagonism O
at O
D2 O
receptors O
in O
the O
mesolimbic O
pathway O
and O
5HT2A O
receptors O
in O
the O
frontal O
cortex O
. O

-DOCSTART- O

swelling B-NEG
of I-NEG
carbuncle I-NEG
caused O
by O
heat B-NEG
toxin I-NEG

-DOCSTART- O

Unspecified B-NEG
Adult I-NEG
Solid I-NEG
Tumor I-NEG
, I-NEG
Protocol I-NEG
Specific I-NEG

-DOCSTART- O

Woman O
, O
Menopausal B-NEG
woman I-NEG

-DOCSTART- O

The O
precise O
mechanism O
of O
action O
has O
not O
been O
fully O
determined O
, O
but O
the O
main O
mechanism O
of O
fluorouracil O
is O
thought O
to O
be O
the O
binding O
of O
the O
deoxyribonucleotide O
of O
the O
drug O
( O
FdUMP O
) O
and O
the O
folate O
cofactor O
, O
N50-methylenetetrahydrofolate O
, O
to O
thymidylate O
synthase O
( O
TS O
) O
to O
form O
a O
covalently O
bound O
ternary O
complex O
. O

This O
results O
in O
the O
inhibition O
of O
the O
formation B-NEU
of I-NEU
thymidylate I-NEU
from O
uracil O
, O
which O
leads O
to O
the O
inhibition O
of O
DNA B-NEU
and I-NEU
RNA I-NEU
synthesis I-NEU
and O
cell O
death O
. O

Fluorouracil O
can O
also O
be O
incorporated O
into O
RNA O
in O
place O
of O
uridine O
triphosphate O
( O
UTP O
) O
, O
producing O
a O
fraudulent B-DNP
RNA I-DNP
and O
interfering O
with O
RNA B-NEU
processing I-NEU
and O
protein B-NEU
synthesis I-NEU
. O

-DOCSTART- O

This O
is O
a O
symptom O
with O
vomiting B-NEG
because O
of O
Cold-Damp B-NEG
. O

-DOCSTART- O

To O
enrich O
yin O
and O
supplement O
kidney B-DNP
, O
clear O
lung B-DNP
and O
moisten O
dryness B-NEU
, O
resolve O
toxin B-NEG
and O
disperse O
swelling B-NEG
. O

-DOCSTART- O

To O
quicken O
blood B-DNP
and O
regulate O
menstruation B-NEU
, O
dissipate O
stasis B-NEG
and O
relieve O
pain B-NEG
. O

-DOCSTART- O

Wind-damp B-NEG
bone O
pain B-NEG
, O
knocks O
and O
falls O
, O
bleeding B-NEG
due O
to O
external O
injury B-NEG
, O
child O
gan O
accumulation O
. O

-DOCSTART- O

Spasticity B-NEG

-DOCSTART- O

To O
dispel O
wind B-NEG
, O
remove O
obstruction O
of O
the O
collaterals O
, O
and O
relieve O
spasms B-NEG
and O
convulsions B-NEG
. O

-DOCSTART- O

A O
symptom O
that O
a O
person O
has O
tightness B-NEG
in I-NEG
the I-NEG
chest I-NEG
and O
does O
not O
feel O
hungry O
. O

-DOCSTART- O

For O
palliative O
, O
not O
definitive O
, O
therapy O
to O
temporarily O
maintain O
the O
patency B-NEG
of I-NEG
the I-NEG
ductus I-NEG
arteriosus I-NEG
until O
corrective O
or O
palliative O
surgery O
can O
be O
performed O
in O
neonates O
who O
have O
congenital B-NEG
heart I-NEG
defects I-NEG
and O
who O
depend O
upon O
the O
patent O
ductus O
for O
survival O
. O
Also O
for O
the O
treatment O
of O
erectile B-NEG
dysfunction I-NEG
due O
to O
neurogenic O
, O
vasculogenic O
, O
psychogenic O
, O
or O
mixed O
etiology O
. O

-DOCSTART- O

To O
warm O
the O
spleen B-DNP
and O
stomach B-DNP
, O
to O
regulate O
the O
adverse O
flow O
of O
the O
stomach O
qi O
, O
and O
to O
restore O
the O
kidney O
yang O
. O

-DOCSTART- O

To O
clear O
heat B-NEU
and O
resolve O
toxin B-NEG
, O
disinhibit O
urine B-NEU
, O
relieve O
cough B-NEG
, O
stanch O
bleeding B-NEG
. O

-DOCSTART- O

Treatment O
of O
edema B-NEG
, O
oliguria B-NEG
, O
arthritis B-NEG
with O
contracture B-NEG
of O
joints O
, O
diarrhea B-NEG
due O
to O
diminished O
function O
of O
the O
spleen B-DNP
, O
lung B-NEG
abscess I-NEG
, O
appendicitis B-NEG
, O
verruca B-NEG
plana I-NEG
. O

-DOCSTART- O

This O
is O
a O
symptom O
with O
pricking O
pain B-NEG
in O
the O
chest O
and O
abdomen O
. O

-DOCSTART- O

Psoriatic B-NEG
Arthritis I-NEG

-DOCSTART- O

Despite O
the O
development O
of O
radiotherapy O
machines O
and O
technologies O
, O
a O
proportion O
of O
patients O
suffer O
from O
radiation-induced O
lymphedema B-NEG
. O

Saireito O
( O
SRT O
) O
is O
a O
traditional O
Japanese O
herbal O
medicine O
that O
has O
been O
used O
for O
treating O
edema B-NEG
and O
inflammation B-NEG
in O
conditions O
such O
as O
nephritic O
disease B-NEG
. O

This O
study O
investigated O
the O
effect O
of O
SRT O
on O
lymphedema B-NEG
caused O
by O
radiotherapy O
. O

Four O
patients O
were O
treated O
with O
SRT O
at O
a O
dose O
of O
9 O
g/day O
. O

The O
severity O
of O
lymphedema O
was O
evaluated O
using O
the O
Common O
Terminology O
Criteria O
for O
Adverse O
Events O
version O
4 O
and O
Numerical O
Rating O
Scale O
before O
and O
after O
SRT O
treatment O
. O

After O
the O
treatment O
with O
SRT O
, O
2 O
of O
4 O
patients O
( O
0.5 O
) O
showed O
apparent O
improvement O
in O
lymphedema B-NEG
. O

One O
of O
the O
cases O
had O
difficulty O
in O
wearing O
the O
custom-made O
thermoplastic O
cast O
, O
but O
after O
SRT O
administration O
, O
he O
could O
wear O
the O
mask O
easily O
. O

One O
case O
decided O
to O
stop O
taking O
SRT O
3 O
days O
after O
initiation O
because O
cough B-NEG
and O
fever B-NEG
appeared O
. O

In O
conclusion O
, O
it O
is O
important O
to O
control O
the O
side O
effects O
of O
radiotherapy O
, O
which O
leads O
to O
improved O
tumor O
control O
rates O
. O

Prospective O
randomized O
studies O
are O
necessary O
to O
confirm O
the O
findings O
of O
this O
case O
series O
study O
. O

-DOCSTART- O

moisten O
the O
liver B-DNP

-DOCSTART- O

general O
weakness B-NEG
and O
weight B-NEU
loss I-NEU

-DOCSTART- O

Purging O
by O
pressure O
and O
by O
removing O
liquid O

-DOCSTART- O

It O
may O
also O
bind O
to O
bacterial O
potassium O
transporters O
, O
thereby O
inhibiting O
their O
function O
. O

-DOCSTART- O

A O
UPLC/Q-TOF-MS/MS O
method O
for O
analyzing O
the O
constituents O
in O
rat O
plasma O
after O
oral O
administration O
of O
Yin O
Chen O
Hao O
Tang O
( O
YCHT O
) O
, O
a O
traditional O
Chinese O
medical O
formula O
, O
has O
been O
established O
. O

The O
UPLC/MS O
fingerprints O
of O
the O
samples O
were O
established O
first O
in O
vitro O
and O
in O
vivo O
, O
with O
45 O
compounds O
in O
YCHT O
and O
21 O
compounds O
in O
rat O
plasma O
after O
oral O
administration O
of O
YCHT O
were O
detected O
. O

Of O
the O
45 O
detected O
compounds O
in O
vitro O
, O
30 O
were O
identified O
, O
and O
all O
of O
the O
21 O
compounds O
detected O
in O
rat O
plasma O
were O
identified O
either O
by O
comparing O
the O
retention O
time O
and O
mass O
spectrometry O
data O
with O
that O
of O
reference O
compounds O
or O
by O
mass O
spectrometry O
analysis O
and O
retrieving O
the O
reference O
literatures O
. O

Of O
the O
identified O
21 O
compounds O
in O
rat O
plasma O
, O
19 O
were O
the O
original O
form O
of O
compounds O
absorbed O
from O
the O
45 O
detected O
compounds O
in O
vitro O
, O
2 O
were O
the O
metabolites O
of O
the O
compounds O
existed O
in O
YCHT O
. O

It O
is O
concluded O
that O
a O
rapid O
and O
validated O
method O
has O
been O
developed O
based O
on O
UPLC-MS/MS O
, O
which O
shows O
high O
sensitivity O
and O
resolution O
that O
is O
more O
suitable O
for O
identifying O
the O
bioactive O
constituents O
in O
plasma O
after O
oral O
administration O
of O
Chinese O
herbal O
medicines O
, O
and O
provides O
helpful O
chemical O
information O
for O
further O
pharmacology O
and O
active O
mechanism O
research O
on O
the O
Chinese O
medical O
formula O
. O

-DOCSTART- O

Other B-DNP
system I-DNP
health I-DNP
, O
Others O

-DOCSTART- O

a O
symptom O
of O
having O
muscular B-NEG
flaccidity I-NEG
due O
to O
deficiency O
of O
Gi O
, O
and O
insufficiency B-NEG
of I-NEG
nourishment I-NEG
in O
organs O
due O
to O
deficiency B-NEG
of I-NEG
blood I-NEG

-DOCSTART- O

shortness B-NEG
of I-NEG
breath I-NEG
with O
chest B-NEG
congested I-NEG

-DOCSTART- O

dysentery B-NEG

-DOCSTART- O

Nausea B-NEG

-DOCSTART- O

cough B-NEG
due O
to O
lung B-NEG
exhaustion I-NEG
syndrome I-NEG

-DOCSTART- O

sores B-NEG
; O
boil B-NEG
suppurative I-NEG
infection I-NEG
on O
the O
body O
surface O
. O
including O
carbuncle B-NEG
, O
furuncle B-NEG
, O
deep-rooted O
carbuncle B-NEG
, O
multiple O
abscess B-NEG
, O
scrofula B-NEG
, O
ulcer B-NEG
. O

-DOCSTART- O

fetal O
irritability B-NEG
; O

threatened B-NEG
abortion I-NEG
; O

excessive O
fetal O
movements O
continuous O
moving O
of O
the O
fetus O
causing O
pain B-NEG
in O
the O
lower O
abdomen O
. O

-DOCSTART- O

Cardiac B-NEG
Output I-NEG
, I-NEG
Low I-NEG

-DOCSTART- O

aversion O
to O
cold B-NEG
; O
severe O
chillness B-NEG
; O
creeping B-NEG
chills I-NEG

-DOCSTART- O

Cardiac B-NEG
carbuncle I-NEG
has O
half O
conscious O
, O
stuffiness B-NEG
in O
the O
heart O
, O
and O
forgetting O
well O
when O
something O
occurred O
. O

-DOCSTART- O

In O
the O
process O
of O
binding O
, O
the O
receptor O
is O
actually O
activated O
- O
causing O
a O
process O
known O
as O
depolarization B-DNP
. O

-DOCSTART- O

invigorate O
waist O
and O
limbs O

-DOCSTART- O

To O
lower O
blood B-NEU
pressure I-NEU
, O
supplement O
liver B-DNP
and O
kidney B-DNP
, O
strengthen O
sinews B-DNP
and O
bones B-DNP
, O
quiet O
fetus O
. O

-DOCSTART- O

To O
dispel O
wind B-NEG
, O
resolve O
phlegm B-NEG
and O
promote O
blood B-NEU
circulation I-NEU
to O
remove O
obstruction B-NEG
in O
the O
channels O
. O

-DOCSTART- O

To O
regulate O
the O
qi O
of O
the O
liver B-DNP
and O
stomach B-DNP
, O
and O
relieve O
pain B-NEG
. O

-DOCSTART- O

pain B-NEG
with O
1 O
hernia B-NEG
2 O
diseases B-NEG
of I-NEG
genitalia I-NEG
3 O
. O
severe O
pain B-NEG
in O
the O
lower O
abdomen O

-DOCSTART- O

eliminate O
vacuity B-NEG
and I-NEG
clod I-NEG
of I-NEG
the I-NEG
spleen I-NEG
and I-NEG
the I-NEG
stomach I-NEG

-DOCSTART- O

Infection B-NEG

-DOCSTART- O

Heartburn B-NEG

-DOCSTART- O

Type B-NEG
1 I-NEG
Diabetes I-NEG
Mellitus I-NEG

-DOCSTART- O

Chronic B-NEG
Viral I-NEG
Hepatitis I-NEG
B I-NEG
Without I-NEG
Delta-agent I-NEG

-DOCSTART- O

wind-cold B-NEG
; O

wind-cold B-NEG
pathogen I-NEG
wind B-NEG
and O
cold B-NEG
blended O
as O
a O
pathogenic O
facto O

-DOCSTART- O

loss B-NEG
of I-NEG
appetite I-NEG

-DOCSTART- O

edema B-NEG

-DOCSTART- O

For O
the O
treatment O
and O
management O
of O
congestive B-NEG
cardiac I-NEG
insufficiency I-NEG
, O
arrhythmias B-NEG
and O
heart B-NEG
failure I-NEG
. O

-DOCSTART- O

Aortic B-NEG
Valve I-NEG
Stenosis I-NEG

-DOCSTART- O

facial B-NEG
hemiparalysis I-NEG
due O
to O
wind B-NEG
stroke I-NEG

-DOCSTART- O

Treatment O
of O
weakness B-NEG
of I-NEG
the I-NEG
spleen I-NEG
and I-NEG
the I-NEG
lung I-NEG
manifested O
by O
shortness B-NEG
of I-NEG
breath I-NEG
, O
cough B-NEG
, O
palpitation B-NEG
, O
anorexia B-NEG
, O
loose B-NEG
stools I-NEG
, O
diabetes B-NEG
caused O
by O
internal O
heat B-NEU
. O

-DOCSTART- O

High-Grade O
Lymphoma B-NEG

-DOCSTART- O

Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Mood O
, O
Physical B-DNP
performance I-DNP
and O
fitness O
, O
Intelligence O
, O
Neurological B-DNP
systems I-DNP
health I-DNP
, O
Strength O
and O
power O
, O
Neurological B-DNP
systems I-DNP
, O
Protective B-NEU
immunity I-NEU
, O
Mental B-DNP
state I-DNP
and I-DNP
performance I-DNP

-DOCSTART- O

blurred B-NEG
vision I-NEG

-DOCSTART- O

Efficacy O
of O
Keishibukuryogan O
, O
a O
traditional O
Japanese O
herbal O
medicine O
, O
in O
treating O
cold B-NEG
sensation I-NEG
and O
numbness B-NEG
after O
stroke B-NEG
: O
clinical O
improvement O
and O
skin O
temperature O
normalization O
in O
22 O
stroke O
patients O
. O

-DOCSTART- O

to O
have O
skin B-NEG
rashes I-NEG
due O
to O
epidemic B-NEG
febrile I-NEG

-DOCSTART- O

Applicable O
to O
cases O
of O
watery B-NEG
diarrhea I-NEG
with O
increased O
gurgling O
sounds O
, O
abdominal B-NEG
pain I-NEG
, O
nausea B-NEG
, O
vomiting B-NEG
, O
vexation B-NEG
, O
thirst B-NEU
, O
yellow B-NEU
and I-NEU
greasy I-NEU
fur I-NEU
, O
soft O
and O
floating O
, O
smooth B-NEU
pulse I-NEU
, O
which O
are O
attributive O
to O
dampness-heat B-NEG
of O
intestines O
and O
stomach O
( O
predominantly O
da O

-DOCSTART- O

food B-NEG
damage I-NEG
; O
injury B-NEG
due O
to O
improper O
diet O
; O
eating B-NEG
food I-NEG
much I-NEG
injury B-NEG
of O
spleen O
and O
stomach O

-DOCSTART- O

a O
disease O
with O
dry O
cough B-NEG
with O
little O
amount O
of O
phlegm B-NEG

-DOCSTART- O

Bacterial B-NEG
infections I-NEG
of O
the O
ear O

-DOCSTART- O

Hepatoma B-NEG

-DOCSTART- O

Seasonal B-NEG
Allergic I-NEG
Rhinitis I-NEG

-DOCSTART- O

insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk I-NEG
, O
Body B-NEU
weight I-NEU
regulation I-NEU
, O
Body B-NEU
weight I-NEU

-DOCSTART- O

To O
benefit O
vital O
Qi O
, O
invigorate O
the O
spleen B-DNP
and O
nourish O
the O
stomach B-DNP
. O

For O
hypofunction B-NEG
of I-NEG
the I-NEG
spleen I-NEG
and I-NEG
stomach I-NEG
, O
peptic B-NEG
ulcer I-NEG
and O
chronic B-NEG
gastritis I-NEG
. O

Recently O
, O
also O
used O
for O
the O
cancers B-NEG
of I-NEG
erophagus I-NEG
, I-NEG
stomach I-NEG
and I-NEG
intestines I-NEG
. O

-DOCSTART- O

deficiency B-NEG
of O
the O
heart O
; O
deficiency B-NEG
syndrome O
of O
the O
heart O
including O
deficiency B-NEG
of O
blood O
and O
Eum O
, O
and O
insufficiency O
of O
Gi O
and O
Yang O
of O
the O
heart O

-DOCSTART- O

Yin O
Chen O
Hao O
Tang O
( O
YCHT O
) O
is O
one O
of O
the O
most O
frequently O
used O
prescriptions O
in O
the O
long O
history O
of O
traditional O
Chinese O
medicine O
practice O
. O

The O
prescription O
contains O
three O
Chinese O
herbs O
, O
namely O
Artemisia O
capillaries O
Thunb O
. O

( O
Compositae O
) O
, O
Rheum O
officinale O
Baillon O
( O
Polygonaceae O
) O
, O
and O
Gardenia O
jasminoids O
Ellis O
( O
Rubiaceae O
) O
, O
and O
has O
been O
widely O
used O
to O
treat O
acute O
hepatitis B-NEG
with O
jaundice B-NEG
. O

In O
this O
study O
, O
the O
in O
vitro O
anti-HSV-1 B-POS
and I-POS
HSV-2 I-POS
activities I-POS
of O
the O
water O
extract O
of O
YCHT O
were O
investigated O
. O

Results O
showed O
that O
YCHT O
water O
extract O
inhibited O
both O
HSV-1 B-NEG
and O
HSV-2 B-NEG
infections O
. O

However O
, O
the O
inhibition O
was O
more O
effective O
against O
HSV-2 B-NEG
than O
against O
HSV-1 B-NEG
. O

The O
IC(50 O
) O
and O
IC(90 O
) O
values O
of O
YCHT O
water O
extract O
against O
HSV-1 B-NEG
infection O
were O
in O
the O
range O
of O
142.5-150.1 O
and O
191.3-393.9 O
microg/ml O
, O
and O
against O
HSV-2 B-NEG
infection O
they O
were O
in O
the O
range O
of O
19.6-29.4 O
and O
42.2-97.7 O
microg/ml O
, O
respectively O
. O

The O
water O
extract O
of O
YCHT O
showed O
no O
cytotoxic O
effect O
at O
a O
concentration O
of O
500 O
microg/ml O
or O
below O
, O
and O
had O
a O
CC(50 O
) O
value O
of O
850.7+/-1.7 O
microg/ml O
. O

The O
prescription O
was O
found O
to O
diminish O
HSV-2 B-NEG
infectivity O
in O
a O
dose-dependent O
manner O
, O
and O
the O
activity O
was O
influenced O
by O
the O
incubation O
periods O
and O
the O
incubation O
temperatures O
. O

Concurrent O
addition O
of O
virus O
with O
YCHT O
or O
pre-treatment O
of O
the O
virus O
with O
the O
prescription O
extract O
both O
protected O
the O
cells O
from O
infection O
. O

In O
summary O
, O
the O
water O
extract O
of O
YCHT O
was O
concluded O
to O
inhibit O
infections O
by O
HSV-1 B-NEG
and O
HSV-2 B-NEG
and O
this O
effect O
was O
likely O
mediated O
through O
direct O
inactivation O
of O
the O
virus B-NEG
infectivity O
. O

-DOCSTART- O

To O
warm O
the O
kidney B-DNP
and O
promote O
virility B-DNP
, O
to O
reduce O
modulation O
, O
and O
to O
induce O
subsidence O
of O
swelling B-NEG
. O

-DOCSTART- O

Traumatic B-NEG
injury I-NEG
with O
ecchymosis B-NEG
, O
swelling B-NEG
and O
pain B-NEG
. O

-DOCSTART- O

Pharyngitis B-NEG
, O
excessive O
sputum B-NEG
blocking O
the O
windpipe O
, O
rapid B-NEG
breathing I-NEG
and O
even O
suffocation B-NEG
. O

-DOCSTART- O

Omeprazole O
is O
a O
proton O
pump O
inhibitor O
that O
suppresses O
gastric B-NEU
acid I-NEU
secretion I-NEU
by O
specific O
inhibition O
of O
the O
H<sup>+</sup>/K<sup>+</sup>-ATPase O
in O
the O
gastric O
parietal O
cell O
. O

By O
acting O
specifically O
on O
the O
proton O
pump O
, O
omeprazole O
blocks O
the O
final O
step O
in O
acid O
production O
, O
thus O
reducing O
gastric B-NEU
acidity I-NEU
. O

-DOCSTART- O

disliking O
wind B-NEG
syndrome I-NEG
due O
to O
external O
and O
internal O
injury B-NEG
. O

-DOCSTART- O

polydipsia B-NEG
due O
to O
high O
fever B-NEG

-DOCSTART- O

precipitation O
of O
blood O
during O
pregnancy B-NEU

-DOCSTART- O

Water O
extract O
of O
Samultang O
reduces O
apoptotic O
cell B-NEU
death I-NEU
by O
h(2)o(2)-induced O
oxidative O
injury O
in O
sk-N-mc O
cells O
. O

-DOCSTART- O

Prednisolone O
can O
inhibit O
leukocyte B-NEG
infiltration I-NEG
at O
the O
site O
of O
inflammation B-NEG
, O
interfere O
with O
mediators O
of O
inflammatory B-NEG
response I-NEG
, O
and O
suppress O
humoral B-NEU
immune I-NEU
responses I-NEU
. O

-DOCSTART- O

Gabapentin O
interacts O
with O
cortical B-DNP
neurons I-DNP
at O
auxillary O
subunits O
of O
voltage-sensitive O
calcium O
channels O
and O
increases O
the O
synaptic B-NEU
concentration I-NEU
of I-NEU
GABA I-NEU
, O
enhances O
GABA B-NEU
responses I-NEU
at O
non-synaptic O
sites O
in O
neuronal O
tissues O
, O
and O
reduces O
the O
release O
of O
mono-amine B-DNP
neurotransmitters I-DNP
. O

Duloxetine O
selectively O
prevents O
the O
reuptake B-NEU
of I-NEU
5-HT I-NEU
and I-NEU
NE I-NEU
via O
transporter O
complexes O
on O
the O
pre-synaptic O
membrane O
, O
thereby O
increasing O
the O
level O
of O
these O
neurotransmitters B-DNP
within O
the O
synaptic O
cleft O
. O

-DOCSTART- O

There O
are O
two O
isoforms O
of O
ACE O
: O
the O
somatic O
isoform O
, O
which O
exists O
as O
a O
glycoprotein O
comprised O
of O
a O
single O
polypeptide O
chain O
of O
1277 O
; O
and O
the O
testicular O
isoform O
, O
which O
has O
a O
lower O
molecular O
mass O
and O
is O
thought O
to O
play O
a O
role O
in O
sperm O
maturation O
and O
binding O
of O
sperm O
to O
the O
oviduct O
epithelium O
. O

Somatic O
ACE O
has O
two O
functionally O
active O
domains O
, O
N O
and O
C, O
which O
arise O
from O
tandem O
gene O
duplication O
. O

Although O
the O
two O
domains O
have O
high O
sequence O
similarity O
, O
they O
play O
distinct O
physiological O
roles O
. O

The O
C-domain O
is O
predominantly O
involved O
in O
blood B-NEU
pressure I-NEU
regulation I-NEU
while O
the O
N-domain O
plays O
a O
role O
in O
hematopoietic B-NEU
stem I-NEU
cell I-NEU
differentiation I-NEU
and I-NEU
proliferation I-NEU
. O

ACE O
inhibitors O
bind O
to O
and O
inhibit O
the O
activity O
of O
both O
domains O
, O
but O
have O
much O
greater O
affinity O
for O
and O
inhibitory O
activity O
against O
the O
C-domain O
. O

Enalaprilat O
, O
the O
principle O
active O
metabolite O
of O
enalapril O
, O
competes O
with O
ATI O
for O
binding O
to O
ACE O
and O
inhibits O
and O
enzymatic B-NEU
proteolysis I-NEU
of I-NEU
ATI I-NEU
to O
ATII O
. O

Decreasing O
ATII B-NEU
levels I-NEU
in O
the O
body O
decreases O
blood B-NEU
pressure I-NEU
by O
inhibiting O
the O
pressor B-NEU
effects I-NEU
of I-NEU
ATII I-NEU
as O
described O
in O
the O
Pharmacology O
section O
above O
. O

Enalapril O
also O
causes O
an O
increase O
in O
plasma B-NEU
renin I-NEU
activity I-NEU
likely O
due O
to O
a O
loss O
of O
feedback O
inhibition O
mediated O
by O
ATII O
on O
the O
release O
of O
renin O
and/or O
stimulation O
of O
reflex O
mechanisms O
via O
baroreceptors O
. O

Enalaprilat's O
affinity O
for O
ACE O
is O
approximately O
200,000 O
times O
greater O
than O
that O
of O
ATI O
and O
300-1000 O
times O
greater O
than O
that O
enalapril O
. O

-DOCSTART- O

Amenorrhea B-NEG
, O
concretion B-NEG
and O
conglomeration B-NEG
, O
knocks B-NEG
and O
falls B-NEG
, O
abdominal B-NEG
pain I-NEG
, O
asthma B-NEG
( O
raw O
) O
, O
blood B-NEG
ejection I-NEG
, O
hematuria B-NEG
, O
hematochezia B-NEG
, O
prolapse B-NEG
of O
rectum O
( O
scorch-fry O
) O
. O

-DOCSTART- O

Hydroflumethiazide O
is O
a O
thiazide O
diuretic O
that O
inhibits O
water B-NEU
reabsorption I-NEU
in O
the O
nephron O
by O
inhibiting O
the O
sodium-chloride B-DNP
symporter I-DNP
( O
SLC12A3 B-DNP
) O
in O
the O
distal O
convoluted O
tubule O
, O
which O
is O
responsible O
for O
5% O
of O
total O
sodium B-NEU
reabsorption I-NEU
. O

Normally O
, O
the O
sodium-chloride B-DNP
symporter I-DNP
transports O
sodium O
and O
chloride O
from O
the O
lumen O
into O
the O
epithelial O
cell O
lining O
the O
distal O
convoluted O
tubule O
. O

The O
energy O
for O
this O
is O
provided O
by O
a O
sodium B-NEU
gradient I-NEU
established O
by O
sodium-potassium O
ATPases O
on O
the O
basolateral O
membrane O
. O

Once O
sodium O
has O
entered O
the O
cell O
, O
it O
is O
transported O
out O
into O
the O
basolateral O
interstitium O
via O
the O
sodium-potassium O
ATPase O
, O
causing O
an O
increase O
in O
the O
osmolarity O
of O
the O
interstitium O
, O
thereby O
establishing O
an O
osmotic B-NEU
gradient I-NEU
for O
water B-NEU
reabsorption I-NEU
. O

By O
blocking O
the O
sodium-chloride B-DNP
symporter I-DNP
, O
Hydroflumethiazide O
effectively O
reduces O
the O
osmotic B-NEU
gradient I-NEU
and O
water B-NEU
reabsorption I-NEU
throughout O
the O
nephron O
. O

-DOCSTART- O

Carotid B-NEG
Artery I-NEG
Stenosis I-NEG

-DOCSTART- O

Tretinoin O
binds O
to O
and O
activates O
retinoic O
acid O
receptors O
( O
RARs O
) O
, O
thereby O
inducing O
changes O
in O
gene O
expression O
that O
lead O
to O
cell O
differentiation O
, O
decreased O
cell O
proliferation O
, O
and O
inhibition O
of O
tumorigenesis B-NEG
. O

-DOCSTART- O

Mouth B-NEG
sore I-NEG
, O
clove B-NEG
sore I-NEG
, O
hemorrhoids B-NEG
, O
scrotal B-NEG
eczema I-NEG
, O
bleeding B-NEG
due O
to O
external B-NEG
injury I-NEG
. O

-DOCSTART- O

This O
is O
a O
syndrome O
with O
a O
pain B-NEG
under O
the O
side O
. O

-DOCSTART- O

difficulty B-NEG
in I-NEG
urination I-NEG

-DOCSTART- O

soothe O
the O
sinews B-DNP
and O
the O
network O
vessels B-NEU

-DOCSTART- O

Used O
principally O
as O
an O
analgesic O
. O

-DOCSTART- O

Hepatitis B-NEG
B I-NEG

-DOCSTART- O

To O
stop O
bleeding B-NEG
and O
promote O
the O
healing O
of O
wounds B-NEG
. O

-DOCSTART- O

exogenous B-NEG
febrile I-NEG
disease I-NEG
of O
four O
seasons O

-DOCSTART- O

lack O
of O
Gi O
; O

asthenic B-NEG
breathing I-NEG
a O
morbid B-NEG
condition I-NEG
chiefly O
manifested O
as O
disinclination B-NEG
ta1k O
, O
low O
voice O
, O
listlessness B-NEG
and O
asthenia B-NEG
, O
lack B-NEG
of I-NEG
strength I-NEG
in O
speaking O
, O
weak O
pulse B-DNP

-DOCSTART- O

The O
exact O
mechanism O
of O
action O
of O
ingenol O
mebutate O
in O
actinic O
keratosis O
is O
unknown O
. O

It O
is O
presumed O
to O
involve O
primary O
necrosis B-NEG
then O
neutrophil-mediated B-NEG
inflammation I-NEG
and O
antibody-dependent B-NEG
cell I-NEG
death I-NEG
of O
residual O
disease B-NEG
cells I-NEG
. O

Additionally O
in O
early O
studies O
, O
PEP005 O
was O
shown O
to O
be O
an O
effective O
activator O
of O
PKC-delta O
and O
PKC-delta O
translocation O
into O
nucleus O
and O
membranes O
. O

PEP005 O
also O
downregulates O
the O
expression B-DNP
and I-DNP
activity I-DNP
of I-DNP
PKC-alpha I-DNP
. O

PEP005 O
induced O
modulation O
of O
PKCs O
leads O
to O
Ras O
/ O
Raf O
/ O
MAPK O
and O
p38 O
activation O
and O
AKT O
/ O
PKB O
inhibition O
. O

-DOCSTART- O

stabilize O
pain B-NEG

-DOCSTART- O

Croton O
seed O
( O
Badou O
) O
is O
used O
with O
Medicated O
leaven O
( O
Shenqu O
) O
, O
Arisaema O
tuber O
with O
bile O
( O
Dannanxing O
) O
and O
Cinnabar O
( O
Zhusha O
) O
in O
the O
formula O
Baochi O
San O
. O

-DOCSTART- O

For O
induction O
and O
maintenance O
in O
the O
treatment O
of O
cytomegalovirus B-NEG
( O
CMV B-NEG
) O
retinitis B-NEG
in O
immunocompromised O
patients O
, O
including O
patients O
with O
acquired B-NEG
immunodeficiency I-NEG
syndrome I-NEG
( O
AIDS B-NEG
) O
. O

Also O
used O
in O
the O
treatment O
of O
severe O
cytomegalovirus B-NEG
( O
CMV B-NEG
) O
disease B-NEG
, O
including O
CMV B-NEG
pneumonia I-NEG
, O
CMV B-NEG
gastrointestinal I-NEG
disease I-NEG
, O
and O
disseminated O
CMV B-NEG
infections I-NEG
, O
in O
immunocompromised O
patients O
. O

-DOCSTART- O

Respiratory B-NEG
Distress I-NEG

-DOCSTART- O

white B-NEG
turbid I-NEG
urine I-NEG

-DOCSTART- O

Colorectal B-NEG
Cancer I-NEG

-DOCSTART- O

Its O
chief O
component O
is O
berberine O
. O

-DOCSTART- O

1 O
To O
remove O
blood B-NEG
stasis I-NEG
and O
alleviate O
pain B-NEG
. O
For O
stomachache B-NEG
, O
headache B-NEG
, O
toothache B-NEG
, O
trauma B-NEG
and O
rheumatism B-NEG
. O
2 O
To O
clear O
heat B-NEU
and O
toxic O
material O
. O
For O
sorethroat B-NEG
, O
aphthae B-NEG
, O
carbuncle B-NEG
, O
burn B-NEG
, O
snake B-NEG
bite I-NEG
, O
dysentery B-NEG
and O
diarrhea B-NEG
. O
3 O
To O
relax O
the O
muscles B-POS
. O
As O
a O
muscle O
relaxant O
for O
restoration O
of O
fracture B-NEG
and O
surgical O
operation O
. O

-DOCSTART- O

Behavioral O
and O
psychological B-NEG
symptoms I-NEG
of I-NEG
dementia I-NEG
( O
BPSD B-NEG
) O
are O
commonly O
seen O
in O
patients O
with O
Alzheimer's B-NEG
disease I-NEG
( O
AD B-NEG
) O
and O
other O
forms O
of O
senile B-NEG
dementia I-NEG
. O

BPSD B-NEG
have O
a O
serious O
impact O
on O
the O
quality O
of O
life O
of O
dementia B-NEG
patients O
, O
as O
well O
as O
their O
caregivers O
. O

However O
, O
an O
effective O
drug O
therapy O
for O
BPSD B-NEG
has O
not O
been O
established O
. O

Recently O
, O
the O
traditional O
Japanese O
medicine O
Yokukansan O
( O
YKS O
, O
Yi-gan O
san O
in O
Chinese O
) O
has O
been O
reported O
to O
improve O
BPSD B-NEG
in O
a O
randomized O
, O
single-blind O
, O
placebo-controlled O
study O
. O

Moreover O
, O
abnormalities B-NEG
of I-NEG
the I-NEG
serotonin I-NEG
( I-NEG
5-HT I-NEG
) I-NEG
system I-NEG
such O
as O
5-HT2A B-DNP
receptors I-DNP
have O
been O
reported O
to O
be O
associated O
with O
BPSD B-NEG
of O
AD B-NEG
patients O
. O

In O
the O
present O
study O
, O
we O
investigated O
the O
effect O
of O
YKS O
on O
head-twitch O
response O
induced O
by O
2,5-dimethoxy-4-iodoamphetamine O
( O
DOI O
, O
5 O
mg/kg O
, O
i.p O
. O
) O
in O
mice O
, O
a O
behavioral O
response O
that O
is O
mediated O
, O
in O
part O
, O
by O
5-HT2A B-DNP
receptors I-DNP
. O

Acute O
treatment O
with O
YKS O
( O
100 O
and O
300 O
mg/kg O
, O
p.o O
. O
) O
had O
no O
effect O
on O
the O
DOI-induced O
head-twitch O
response O
, O
whilst O
14 O
days O
repeated O
treatment O
with O
YKS O
( O
300 O
mg/kg O
, O
p.o O
. O
) O
significantly O
inhibited O
this O
response O
. O

Moreover O
, O
repeated O
treatment O
with O
YKS O
( O
300 O
mg/kg O
, O
p.o O
. O
) O
decreased O
expression O
of O
5-HT2A B-DNP
receptors I-DNP
in O
the O
prefrontal O
cortex O
, O
which O
is O
part O
of O
the O
circuitry O
mediating O
the O
head-twitch O
response O
. O

These O
findings O
suggest O
that O
the O
inhibition O
of O
DOI-induced O
head-twitch O
response O
by O
YKS O
may O
be O
mediated O
, O
in O
part O
, O
by O
altered O
expression O
of O
5-HT2A B-DNP
receptors I-DNP
in O
the O
prefrontal O
cortex O
, O
which O
suggests O
the O
involvement O
of O
the O
5-HT B-DNP
system I-DNP
in O
psychopharmacological O
effects O
of O
YKS O
. O

-DOCSTART- O

Sore B-NEG
Throat I-NEG
Due O
to O
a O
Common O
Cold O

-DOCSTART- O

Treatment O
of O
loss B-NEG
of I-NEG
consciousness I-NEG
in O
stroke B-NEG
and O
epilepsy B-NEG
, O
sore B-NEG
throat I-NEG
, O
dyspnea B-NEG
and O
cough B-NEG
with O
phlegm B-NEG
difficult O
to O
spit O
out O
, O
constipation B-NEG
, O
external O
use O
for O
subcutaneous B-NEG
pyogenic I-NEG
infections I-NEG
. O

-DOCSTART- O

retention B-NEG
or I-NEG
stagnancy I-NEG
of I-NEG
undigested I-NEG
food I-NEG

-DOCSTART- O

For O
promoting O
diuresis B-NEU
and O
desolving O
inflammation B-NEG
. O

-DOCSTART- O

blood B-NEG
vomiting I-NEG

-DOCSTART- O

burn O

-DOCSTART- O

Investigated O
for O
use O
/ O
treatment O
in O
infectious B-NEG
and O
parasitic B-NEG
disease I-NEG
( O
unspecified O
) O
and O
pediatric O
indications O
. O

-DOCSTART- O

Hyperuricemia B-NEG

-DOCSTART- O

seven O
injuries B-NEG
; O
seven O
kinds O
of O
impairments B-NEG

-DOCSTART- O

To O
expel O
wind B-NEG
and O
heat B-NEU
, O
purge O
pathogenic O
fire O
and O
relax O
the O
bowels B-NEG
. O

-DOCSTART- O

disperse O
cold B-NEG
and O
eliminate O
dampness B-NEU

-DOCSTART- O

Digestant O
. O

-DOCSTART- O

vertigo B-NEG
due O
to O
wind-phlegm B-NEG

-DOCSTART- O

metrorrhagia B-NEG
and O
metrostaxis B-NEG

-DOCSTART- O

Chronic B-NEG
Hepatitis I-NEG

-DOCSTART- O

Effects O
of O
tokishakuyakusan O
, O
Keishibukuryogan O
and O
Unkeito O
on O
DNA B-NEU
polymerase I-NEU
alpha I-NEU
activity I-NEU
in O
uteri O
of O
pregnant O
mare's O
serum O
gonadotropin-treated O
immature O
rats O
. O

-DOCSTART- O

disperse O
wind B-NEG
and O
eliminate O
dampness B-NEU

-DOCSTART- O

Blockade O
of O
dopaminergic O
D2 O
receptors O
in O
the O
limbic B-DNP
system I-DNP
alleviates O
positive O
symptoms O
of O
schizophrenia B-NEG
such O
as O
hallucinations B-NEG
, O
delusions B-NEG
, O
and O
erratic B-NEG
behavior I-NEG
and O
speech O
. O
Blockade O
of O
serotonergic O
5-HT O
2 O
receptors O
in O
the O
mesocortical B-DNP
tract I-DNP
, O
causes O
an O
excess O
of O
dopamine O
and O
an O
increase O
in O
dopamine O
transmission O
, O
resulting O
in O
an O
increase O
in O
dopamine O
transmission O
and O
an O
elimination O
of O
core O
negative O
symptoms O
. O
Dopamine O
receptors O
in O
the O
nigrostriatal O
pathway O
are O
not O
affected O
by O
risperidone O
and O
extrapyramidal O
effects O
are O
avoided O
. O
Like O
other O
5-HT O
2 O
antagonists O
, O
risperidone O
also O
binds O
at O
alpha(1)-adrenergic O
receptors O
and O
, O
to O
a O
lesser O
extent O
, O
at O
histamine O
H1 O
and O
alpha(2)-adrenergic O
receptors O
. O

-DOCSTART- O

asthma B-NEG

-DOCSTART- O

It O
means O
not O
shiny O
hair O

-DOCSTART- O

epigastric B-NEG
fullness I-NEG
; O
stuffiness B-NEG
in O
the O
gastric O
region O

-DOCSTART- O

HGB-TR2J O
binds O
TRAIL O
Receptor O
2 O
with O
high O
affinity O
, O
induces O
apoptosis B-NEU
and O
has O
anti-tumor B-POS
activity I-POS
, O
both O
as O
a O
single O
agent O
and O
in O
combination O
with O
chemotherapy O
. O

HGB-TR2J O
mimics O
the O
activity O
of O
native O
TRAIL O
( O
tumor O
necrosis O
factor-related O
apoptosis-inducing O
ligand O
) O
and O
, O
thus O
, O
is O
considered O
an O
agonistic O
antibody O
. O

Numerous O
nonclinical O
studies O
have O
shown O
that O
cell O
lines O
derived O
from O
a O
broad O
array O
of O
solid O
and O
hematological B-NEG
human I-NEG
tumors I-NEG
, O
including O
lung O
, O
colon O
, O
breast O
, O
multiple O
myeloma B-NEG
, O
prostate O
and O
pancreas O
, O
are O
sensitive O
to O
killing O
by O
apoptosis O
( O
programmed O
cell O
death O
) O
induced O
by O
native O
TRAIL O
or O
by O
agonistic O
antibodies O
to O
TRAIL O
Receptors O
1 O
and O
2.2-24 O
. O

-DOCSTART- O

relieve O
toxicity B-NEG
and O
alleviate O
edema B-NEG

-DOCSTART- O

Dihydroergotamine O
is O
a O
5-HT1D O
receptor O
agonists O
used O
for O
migraine O
, O
activation O
of O
5-HT1D O
receptors O
located O
on O
intracranial O
blood B-DNP
vessels I-DNP
, O
leads O
to O
vasoconstriction B-DNP
; O
activation O
of O
5-HT1D O
receptors O
on O
sensory O
nerve O
endings O
of O
the O
trigeminal O
system O
results O
in O
the O
inhibition O
of O
pro-inflammatory O
neuropeptide O
release O
. O

-DOCSTART- O

For O
bacterial B-NEG
infections I-NEG
of O
eyes O

-DOCSTART- O

For O
the O
treatment O
of O
moderate O
and O
severe O
hypertension B-NEG
, O
either O
alone O
or O
as O
an O
adjunct O
, O
and O
for O
the O
treatment O
of O
renal B-NEG
hypertension I-NEG
. O

-DOCSTART- O

For O
the O
symptomatic B-POS
relief I-POS
of O
pain B-NEG
, O
burning B-NEG
, O
urgency B-NEG
, O
frequency O
, O
and O
other O
discomforts B-NEG
arising O
from O
irritation B-NEG
of O
the O
lower O
urinary O
tract O
mucosa O
caused O
by O
infection B-NEG
, O
trauma B-NEG
, O
surgery O
, O
endoscopic O
procedures O
, O
or O
the O
passage O
of O
sounds O
or O
catheters O
. O

-DOCSTART- O

warm O
the O
lung B-DNP

-DOCSTART- O

To O
eliminate O
blood B-NEG
stasis I-NEG
with O
strong O
effect O
, O
promote O
the O
flow O
of O
qi O
, O
remove O
the O
retention B-NEG
of I-NEG
undigested I-NEG
food I-NEG
, O
and O
relieve O
pain B-NEG
. O

-DOCSTART- O

Postreperfusion B-NEG
Syndrome I-NEG

-DOCSTART- O

Ribavirin O
triphosphate O
is O
a O
potent O
competitive O
inhibitor O
of O
inosine O
monophosphate O
dehydrogenase O
, O
viral O
RNA O
polymerase O
and O
mRNA O
guanylyltransferase O
( O
viral O
) O
and O
can O
be O
incorporated O
into O
RNA O
in O
RNA O
viral O
species O
. O

Sofosbuvir O
is O
a O
nucleotide O
analogue O
inhibitor O
of O
the O
hepatitis O
C O
virus O
polymerase O
which O
is O
a O
RNA-dependent O
RNA O
polymerase O
critical O
for O
the O
viral O
cycle O
. O

Alfa O
interferons O
bind O
to O
specific O
cell-surface O
receptors O
, O
resulting O
in O
the O
transcription O
and O
translation O
of O
genes O
whose O
protein O
products O
mediate O
antiviral O
, O
antiproliferative O
, O
anticancer O
, O
and O
immune-modulating O
effects O
. O

-DOCSTART- O

abdominal B-NEG
mass I-NEG

-DOCSTART- O

general O
edema B-NEG
with O
abdominal B-NEG
distension I-NEG

-DOCSTART- O

Cancer B-NEG

-DOCSTART- O

vomiting B-NEG
due O
to O
heat B-NEU
in I-NEU
the I-NEU
stomach I-NEU

-DOCSTART- O

1 O
Inhibiting O
sarcoma180 O
and O
cervix O
carcinoma14 O
in O
mice O
and O
L16 O
cells O
isolated O
from O
human O
liver B-NEG
cancer I-NEG
. O
2 O
. O
Promoting O
the O
adrenocortical B-DNP
function I-DNP
in O
mice O
. O
3 O
. O
Promoting O
metabolism B-NEU
and O
reticuloendothelial B-DNP
function I-DNP
. O

-DOCSTART- O

1 O
Analgeic B-NEG
. O
2 O
Sedative B-NEG
. O
3 O
Antispasmodic B-NEG

-DOCSTART- O

This O
is O
a O
syndrome B-NEG
with I-NEG
bloat I-NEG
and I-NEG
fullness I-NEG
in O
abdominal O
region O
. O

-DOCSTART- O

Solid O
Tumors B-NEG

-DOCSTART- O

In O
order O
to O
investigate O
the O
characteristic O
of O
optical O
properties O
of O
Asian O
dust O
particles O
, O
the O
atmospheric O
aerosol O
vertical O
profile O
was O
measured O
with O
the O
multi-wavelength O
LIDAR O
system O
, O
at O
the O
Gosan O
super O
site O
( O
33 O
degrees O
17'N O
, O
126 O
degrees O
10'E O
) O
in O
Jeju O
Island O
, O
Korea O
, O
during O
the O
ACI-Asia O
intensive O
observation O
period O
, O
11 O
42798 O
May O
2001 O
. O

An O
air O
mass O
backward O
trajectory O
analysis O
, O
using O
Hysplit-4 O
, O
was O
carried O
out O
to O
track O
the O
aerosol O
plume O
, O
with O
high O
mass O
loading O
, O
from O
the O
Chinese O
desert O
regions O
during O
the O
period O
of O
Asian O
dust O
storm O
events O
. O

Vertical O
atmospheric O
aerosol O
profiles O
on O
three O
major O
Asian O
dust O
storm O
event O
days O
, O
22 O
March O
and O
13 O
and O
26 O
April O
2001 O
, O
have O
been O
analyzed O
. O

The O
LIDAR-derived O
aerosol O
optical O
depth O
values O
were O
compared O
with O
those O
measured O
by O
a O
collocated O
sunphotometer O
. O

-DOCSTART- O

Quality O
of O
life O

-DOCSTART- O

TBC3711 O
is O
a O
small O
molecule O
that O
blocks O
the O
action O
of O
endothelin B-DNP
, O
a O
potent O
mediator O
of O
blood B-NEU
vessel I-NEU
constriction I-NEU
and O
growth O
of O
smooth O
muscle O
in O
vascular B-DNP
walls I-DNP
. O
It O
is O
a O
next-generation O
endothelin O
A O
antagonist O
which O
possesses O
high O
oral O
bioavailability O
and O
is O
more O
selective O
and O
potent O
than O
THELIN(tm O
) O
( O
sitaxsentan O
sodium O
) O
Encysive's O
oral O
treatment O
for O
pulmonary B-NEG
arterial I-NEG
hypertension I-NEG
. O
TBC3711 O
is O
greater O
than O
100,000-fold O
selective O
in O
the O
targeting O
of O
the O
endothelin O
A O
receptor O
versus O
the O
endothelin O
B O
receptor O
. O

-DOCSTART- O

dispel O
wind B-NEG
and O
eliminate O
dampness B-NEU

-DOCSTART- O

Endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Reproductive B-DNP
systems I-DNP
, O
Blood B-NEU
pressure I-NEU
, O
Lipid O
profile O
, O
Overall O
CVD B-NEG
, O
Diet B-NEG
related I-NEG
cardiovascular I-NEG
disease I-NEG
, O
Others O
, O
Hemostatic B-DNP
function I-DNP
, O
Protective O
immunity B-NEU

-DOCSTART- O

Treatment O
of O
attack O
of O
damp-heat B-NEG
manifested O
by O
stuffiness B-NEG
and O
fullness O
sensation O
in O
the O
abdomen B-DNP
, O
or O
causing O
acute B-NEG
dysentery I-NEG
of O
jaundice B-NEG
, O
high O
fever B-NEG
accompained O
by O
impairment B-NEG
of O
conciousness B-DNP
, O
fidgetness O
and O
insomnia B-NEG
due O
to O
exuberant O
fire O
, O
spitting B-NEG
of I-NEG
blood I-NEG
and O
epistaxis B-NEG
caused O
by O
heat B-NEU
in O
the O
blood O
, O
inflammation B-NEG
of O
the O
eye O
, O
acid B-NEG
regurgitation I-NEG
, O
toothache B-NEG
, O
diabetes B-NEG
, O
carbuncles B-NEG
and O
sores B-NEG
, O
external O
use O
for O
eczema B-NEG
and O
other O
skin B-NEG
diseases I-NEG
with O
exudation O
, O
purulent B-POS
discharge I-POS
from O
the O
ear O
. O
Rhizoma O
Coptidis O
( O
processed O
with O
wine O
) O
Inflammation B-NEG
of O
the O
eye O
, O
ulcers B-NEG
in O
the O
mouth O
. O
Rhizoma O
Coptidis O
( O
processed O
with O
ginger O
) O
Stuffiness O
and O
fullness O
sensation O
in O
the O
abdomen B-DNP
with O
nausea B-NEG
and O
vomiting B-NEG
caused O
by O
damp-heat B-NEG
in O
combination O
with O
cold B-NEG
. O

-DOCSTART- O

Purging B-POS
by O
aggression O

-DOCSTART- O

This O
is O
running O
a O
fever B-NEG
due O
to O
epidemic B-NEG
. O

-DOCSTART- O

Prednisone O
enters O
the O
nucleus O
where O
it O
binds O
to O
and O
activates O
specific O
nuclear O
receptors O
, O
resulting O
in O
an O
altered O
gene B-DNP
expression I-DNP
and O
inhibition O
of O
proinflammatory B-NEU
cytokine I-NEU
production I-NEU
. O

-DOCSTART- O

reinforce O
the O
kidney B-DNP

-DOCSTART- O

